[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 343
1. Stav D, Bar I, Sandbank J: Usefulness of CDK5RAP3, CCNB2, and RAGE genes for the diagnosis of lung adenocarcinoma. Int J Biol Markers; 2007 Apr-Jun;22(2):108-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of CDK5RAP3, CCNB2, and RAGE genes for the diagnosis of lung adenocarcinoma.
  • We used oligonucleotide microarrays with probe sets to 22,283 genes to analyze the gene expression profile of lung adenocarcinoma.
  • Cancerous and noncancerous tissue samples were obtained from 23 patients with stage I or II lung cancer; 18 tissue pairs and 5 cancerous tissues.
  • The combined expression of the 2 cell cycle genes was found to be statistically significant for differentiating between cancerous and noncancerous tissues.
  • We therefore conclude that these 3 genes may be used as a very reliable biomarker of lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Cyclin B / genetics. Intracellular Signaling Peptides and Proteins / genetics. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. Nerve Tissue Proteins / genetics. Receptors, Immunologic / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549666.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCNB2 protein, human; 0 / CDK5RAP3 protein, human; 0 / Cyclin B; 0 / Cyclin B2; 0 / Genetic Markers; 0 / Glycation End Products, Advanced; 0 / Intracellular Signaling Peptides and Proteins; 0 / Nerve Tissue Proteins; 0 / Receptor for Advanced Glycation End Products; 0 / Receptors, Immunologic
  •  go-up   go-down


2. Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, Uchida O, Usuda J, Kato H: The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg; 2007 Apr;13(2):73-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer.
  • Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all lung cancers, with patients having a poor prognosis.
  • Approximately one third of NSCLC patients present with early-stage disease in which potentially curative resection and multi-modality therapy.
  • Although adjuvant chemotherapy is the standard practice for patients with stages I-III breast and colorectal cancer, the therapeutic efficacy of adjuvant chemotherapy, following complete surgical resection of early stage NSCLC, has not been fully established.
  • Several prospective randomized trials for patients with early stage NSCLC (stages I-IIIA) have confirmed a survival benefit with cisplatin-based adjuvant chemotherapy, as demonstrated in the 1995 meta-analysis performed by the NSCLC Collaborative Group.
  • Studies from Japan have reported that adjuvant therapy with uracil-tegaful (UFT) afforded an improvement of 4% in the 5-year survival rate and a relative risk reduction of 26% in mortality at 5 years among patients with T1-2N0 (stage I) disease.
  • In particular, the Japan Lung Cancer Research Group has demonstrated an improvement in the 5-year survival rate of 11%, favoring chemotherapy with UFT in the subset of patients with T2N0 (stage IB) disease.
  • The Lung Adjuvant Cisplatin Evaluation (LACE), which was based on a pooled analysis of five randomized trials, has demonstrated that cisplatin-based adjuvant chemotherapy improved survival in patients with completely resected NSCLC.
  • This benefit depended on stage, being greatest in patients with stage II or IIIA disease.
  • This analysis has suggested that platinum-based adjuvant chemotherapy may have no benefit for patients with stage IA and only a marginal benefit for patients with stage IB.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / mortality

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17505412.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 18
  •  go-up   go-down


3. Gascon P, Pirker R, Del Mastro L, Durrwell L: Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study. Ann Oncol; 2010 Oct;21(10):2029-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study.
  • The objective of this study was to select a starting dose of CERA for the treatment of anemia in non-small-cell lung cancer (NSCLC) patients.
  • PATIENTS AND METHODS: The study was an open-label randomized phase II trial containing four treatment groups of patients with anemia and stage IIIB or IV NSCLC.
  • CONCLUSION: In this phase II study in patients with stage IIIB or IV NSCLC receiving chemotherapy, none of the four treatment arms showed an adequate increase in mean Hb level.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20335369.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / continuous erythropoietin receptor activator; 11096-26-7 / Erythropoietin; 30IQX730WE / Polyethylene Glycols
  •  go-up   go-down


Advertisement
4. Kusumoto S, Hirose T, Fukayama M, Kataoka D, Hamada K, Sugiyama T, Shirai T, Yamaoka T, Okuda K, Ohnishi T, Ohmori T, Kadokura M, Adachi M: Induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer. Oncol Rep; 2009 Nov;22(5):1157-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer.
  • We examined the efficacy and toxicity of a divided schedule of cisplatin and vinorelbine with concurrent radiotherapy followed by surgery in patients with locally advanced non-small cell lung cancer (NSCLC).
  • Patients with clinical stage IIIA or IIIB NSCLC were eligible if they had a performance status of 0 or 1, were 75 years or younger, and had adequate organ function.
  • The median survival time was 36 months (range, 4-78 months), the 2-year survival rate was 74%, and the median time to disease progression was 15 months (range, 2-59 months).
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Squamous Cell / therapy. Lung Neoplasms / therapy


5. Maddau C, Confortini M, Bisanzi S, Janni A, Montinaro F, Paci E, Pontenani G, Rulli P, Salani A, Zappa M, Benvenuti A, Carozzi FM: Prognostic significance of p53 and Ki-67 antigen expression in surgically treated non-small cell lung cancer: immunocytochemical detection with imprint cytology. Am J Clin Pathol; 2006 Mar;125(3):425-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of p53 and Ki-67 antigen expression in surgically treated non-small cell lung cancer: immunocytochemical detection with imprint cytology.
  • The purpose of this study was to determine the prognostic significance of the expression of p53 and Ki-67 in non-small cell lung cancer (NSCLC) using immunocytochemical detection.
  • Overexpression of p53 was associated significantly with worse patient outcome in stage I disease, whereas no excess risk was evident in stage II and III cases.
  • The excess risk in stage I cases with p53 and Ki-67 overexpression was observed only in adenocarcinoma.
  • These findings are in agreement with other retrospective studies and support the hypothesis that p53 alteration may have different roles in adenocarcinoma and in squamous cell carcinoma, such as a carcinogenic factor for both cellular types but progression only for adenocarcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Ki-67 Antigen / metabolism. Lung Neoplasms / pathology. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613347.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


6. Endo S, Saito N, Hasegawa T, Sato Y, Sohara Y: Pulmonary cryptococcosis mimicking pulmonary metastases in a patient treated with Tegafur-uracil after lung cancer surgery. Jpn J Thorac Cardiovasc Surg; 2005 Jul;53(7):369-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary cryptococcosis mimicking pulmonary metastases in a patient treated with Tegafur-uracil after lung cancer surgery.
  • A 71-year-old man who had undergone surgery for stage II adenocarcinoma of the lung followed by adjuvant tegafur-uracil (UFT; 300 mg/day) therapy was admitted.
  • Physicians need to be aware of the possibility of pulmonary cryptococcosis mimicking pulmonary metastases in patients treated with UFT after surgery for lung cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cryptococcosis / diagnosis. Lung Diseases, Fungal / diagnosis. Lung Neoplasms / diagnosis. Lung Neoplasms / therapy

  • Genetic Alliance. consumer health - Cryptococcosis.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1967 Oct;67(4):724-32 [6069972.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1992 Mar;30(3):393-401 [1569717.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 1998 Dec;36(12 ):1038-42 [10064958.001]
  • [Cites] AJR Am J Roentgenol. 1984 May;142(5):893-6 [6609567.001]
  • [Cites] J Comput Assist Tomogr. 2002 May-Jun;26(3):330-4 [12016357.001]
  • [Cites] Br J Radiol. 2002 Mar;75(891):275-8 [11932223.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] Chest. 2003 Dec;124(6):2143-7 [14665493.001]
  • [Cites] Gan To Kagaku Ryoho. 1988 Jun;15(6):1915-20 [3132895.001]
  • (PMID = 16095237.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 1-UFT protocol
  •  go-up   go-down


7. Ypma PF, Wijermans PW, Koppen H, Sillevis Smitt PA: Paraneoplastic cerebellar degeneration preceding the diagnosis of Hodgkin's lymphoma. Neth J Med; 2006 Jul-Aug;64(7):243-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PCD can accompany different kinds of neoplasms including small cell lung cancer, adenocarcinoma of the breast and ovary, and Hodgkin's lymphoma.
  • The search for Hodgkin's disease as concomitant disorder was then started and resulted in stage II B disease.


8. Ulmeanu R, Mihăltan F, Crişan E, Alexe M, Grigore P, Andreescu I, Galbenu P, Leonte D: [Practical issues of transbronchial lung biopsy (TLB) in pneumology]. Pneumologia; 2007 Apr-Jun;56(2):59-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Practical issues of transbronchial lung biopsy (TLB) in pneumology].
  • METHOD: We present a survey of 78 TLB which have been performed in Bronchology Service (during 2003-2005) for diffuse interstitial lung diseases--70 cases or located diseases--8 cases; TLB was not performed for solitary peripherally opacities because we have no radiological device with mobile arm (for good position of forceps).
  • RESULTS: In 78% of cases we obtained illustrative lung tissue and in 22% of cases we prelevated just bronchial wall.
  • Histological confirmation was obtained for 53% of cases; 47% of cases have as result lung tissue without significant modifications.
  • The diagnosis of lung pathology was: diffuse lung fibrosis, tuberculosis, sarcoidosis stage II-III, malignant lymphoma, carcinomatosis, undifferentiated carcinoma, bronchioloalveolar carcinoma, squamous carcinoma, adenocarcinoma.
  • [MeSH-major] Biopsy, Needle / methods. Bronchoscopy. Lung Diseases / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Aged. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Granulomatosis with Polyangiitis / pathology. Health Surveys. Humans. Lung Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Practice Guidelines as Topic. Pulmonary Fibrosis / pathology. Sarcoidosis, Pulmonary / pathology. Sensitivity and Specificity. Tuberculosis, Pulmonary / pathology

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019749.001).
  • [ISSN] 2067-2993
  • [Journal-full-title] Pneumologia (Bucharest, Romania)
  • [ISO-abbreviation] Pneumologia
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


9. Reynolds C, Barrera D, Jotte R, Spira AI, Weissman C, Boehm KA, Pritchard S, Asmar L: Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. J Thorac Oncol; 2009 Dec;4(12):1537-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
  • INTRODUCTION: Carboplatin/paclitaxel chemotherapy with bevacizumab is an accepted standard treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
  • This trial evaluated the combination of nab-paclitaxel, carboplatin, and bevacizumab in advanced (stage IIIB/IV) nonsquamous NSCLC.
  • METHODS: Fifty patients with stage IIIB/IV NSCLC were enrolled between October 2005 and April 2006; 48 were treated with nab-paclitaxel 300 mg/m2, carboplatin area under the curve = 6, and bevacizumab 15 mg/kg every 21 days until progression or intolerable toxicity, up to 4 cycles; an additional 2 cycles could be administered to responding patients and the physician's discretion; maintenance bevacizumab was not administered.
  • Patient demographics included: 56% female, median age 67 years (range, 32-83), performance status 0 (52%) or 1 (48%), adenocarcinoma 86%, and stage IV disease 82%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Nanoparticles / administration & dosage. Paclitaxel / administration & dosage
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / mortality. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Aged, 80 and over. Albumin-Bound Paclitaxel. Albumins / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Carboplatin / administration & dosage. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Quality of Life. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19887966.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Albumin-Bound Paclitaxel; 0 / Albumins; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Zhang Z, Chen Y, Chen Y, Jeter M, Hofstetter WL, Ajani J, Swisher SG, Chang JY, Allen PK, Cox JD, Komaki R, Liao ZX: Outcomes with esophageal cancer radiation therapy. J Thorac Oncol; 2009 Jul;4(7):880-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Men make up 75% or more of the patients with esophageal cancer, most patients have adenocarcinoma in the gastroesophageal junction, and almost 75% have stage II or III disease.
  • CONCLUSION: Although fully delineated comparisons must await incorporation and study of data through 2007, this analysis suggests that multimodality management that has been adapted in recent years may be associated with the improvements in outcomes of these cases of largely stage II and III esophageal adenocarcinoma found at the gastroesophageal junction.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19458557.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K: Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Hepatogastroenterology; 2008 Sep-Oct;55(86-87):1530-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
  • However, the clinical significance of the expression of MDR-related proteins p-glycoprotein (PGP), glutathione-s-transferases (GST-pi), topoisomerase-II (Topo-II) and lung resistance protein (LRP) in primary gastric cardiac adenocarcinoma (PGCA) remains unclear.
  • The expression of PGP, GST-pi, Topo-II and LRP in formalin-fixed paraffin-embedded tissue sections was determined by a labelled streptavidin-biotin immunohistochemical technique, and the results were analyzed in correlation with clinicopathological data.
  • RESULTS: The positive rates of expression of PGP, GST-pi, Topo-II and LRP in malignant tissues (49.2%, 75.4%, 68.1% and 58%, respectively) were all higher than that of the normal tissues (0, 30%, 20% and 0, respectively, P<0.01).
  • GST-pi expression status progressively increased with increasing differentiated degree (40%, 75.8% and 88.5%, P<0.05) and clinico pathologic stage (staging 1/2 vs. 3/4, 57.1% vs. 83.3%, P<0.05).
  • The expression of Topo-II was associated with increasing differentiated degree (33.3%, 69.7% and 80.7%, P<0.01).
  • No significant differences with Topo-II expression was found in relation to the clinicopathologic stage (staging 1/2 vs. 3/4, 57.1% vs. 72.9%, P>0.05) and lymphatic metastasis (with vs. without metastasis, 65.0% vs. 72.4%, P>0.05).
  • Moreover, a significant difference with the expression of LRP was found in relation to the clinicopathologic stage (staging 1/2 vs. 3/4, 38% vs. 66.6%, P<0.05), and lymphatic metastasis (with vs. without metastasis, 70.0% vs. 41.4%, P<0.05).
  • The positive rates of co-expression of PGP and GST-pi, PGP and Topo-II, PGP and LRP, GST-pi and Topo-II, LRP and GST-pi, LRP and Topo-II, PGP, GST-pi, Topo-II and LRP in malignant cells were 23.2%, 15.9%, 11.6%, 13.0%, 26.1%, 7.24%, 5.8%, respectively.
  • CONCLUSIONS: MDR-related proteins PGP, GST-pi, Topo-II and LRP are involved in multiple mechanisms of drug resistance in PGCA.
  • Combined determination of PGP, GST-pi, Topo-II and LRP may be prospectively valuable for optimizing the chemotherapy regimes, developing high quality anti-cancer drugs, and further predicting the outcomes of those patients with PGCA.
  • [MeSH-major] Adenocarcinoma / chemistry. Cardia / chemistry. DNA Topoisomerases, Type II / analysis. Glutathione S-Transferase pi / analysis. P-Glycoprotein / analysis. Stomach Neoplasms / chemistry. Vault Ribonucleoprotein Particles / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102336.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


12. Rades D, Setter C, Dunst J, Dahl O, Schild SE, Noack F: Prognostic impact of VEGF and VEGF receptor 1 (FLT1) expression in patients irradiated for stage II/III non-small cell lung cancer (NSCLC). Strahlenther Onkol; 2010 Jun;186(6):307-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of VEGF and VEGF receptor 1 (FLT1) expression in patients irradiated for stage II/III non-small cell lung cancer (NSCLC).
  • This study investigated the impact of tumor expression of VEGF and FLT1 on outcomes in 61 patients irradiated for stage II/III non-small cell lung cancer (NSCLC).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / pathology. Lung Neoplasms / radiotherapy. Vascular Endothelial Growth Factor A / analysis. Vascular Endothelial Growth Factor Receptor-1 / analysis
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Aged. Biopsy, Needle. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / radiotherapy. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Female. Humans. Immunoenzyme Techniques. Lung / pathology. Male. Middle Aged. Neoplasm Staging. Pneumonectomy. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tuberk Toraks. 2004;52(4):323-32 [15558354.001]
  • [Cites] Strahlenther Onkol. 2008 Feb;184(2):61-6 [18259696.001]
  • [Cites] Strahlenther Onkol. 2009 Apr;185(4):231-4 [19370425.001]
  • [Cites] Br J Radiol. 2004 Jan;77(913):43-8 [14988137.001]
  • [Cites] Strahlenther Onkol. 2002 Dec;178(12):727-31 [12491062.001]
  • [Cites] Arch Bronconeumol. 2003 Feb;39(2):81-6 [12586048.001]
  • [Cites] Strahlenther Onkol. 2008 Jan;184(1):8-14 [18188517.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2337-45 [10590376.001]
  • [Cites] Arch Environ Health. 1985 Nov-Dec;40(6):330-3 [4083915.001]
  • [Cites] Anasthesiol Intensivmed Notfallmed Schmerzther. 1991 Jun;26(4):186-90 [1892968.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1134-42 [18258387.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1161-8 [10741747.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):3977-84 [12553021.001]
  • [Cites] Strahlenther Onkol. 2008 Jan;184(1):36-40 [18188521.001]
  • [Cites] Strahlenther Onkol. 2009 Jan;185(1):27-33 [19224144.001]
  • [Cites] G Ital Med Lav. 1987 Jan;9(1):11-4 [3505219.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):159-63 [8417381.001]
  • [Cites] Bull Exp Biol Med. 2003 May;135(5):478-81 [12910290.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Nov;8(11):1981-97 [6759484.001]
  • [Cites] Int J Mol Med. 2004 Sep;14(3):389-95 [15289890.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1544-9 [12697879.001]
  • [Cites] BMC Public Health. 2006 Jul 18;6:189 [16848898.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1677-84 [16532435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1112-9 [16682148.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):221-32 [17481705.001]
  • [Cites] Strahlenther Onkol. 2008 Nov;184(11):605-9 [19016020.001]
  • [Cites] J Pathol. 1999 Aug;188(4):369-77 [10440746.001]
  • [Cites] Strahlenther Onkol. 2008 Aug;184(8):416-20 [18956519.001]
  • (PMID = 20437013.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  •  go-up   go-down


13. Adelstein DJ, Rice TW, Rybicki LA, Saxton JP, Videtic GM, Murthy SC, Mason DP, Rodriguez CP, Ives DI: Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol; 2009 Oct;4(10):1264-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction.
  • INTRODUCTION: Mature results are presented from a phase II trial of postoperative concurrent chemoradiotherapy in patients with poor-prognosis cancer of the esophagus and gastroesophageal junction after primary surgical resection.
  • METHODS: Resected patients with a pathologic stage of T3, N1, or M1a were eligible for this trial.
  • The median age was 59 (range, 33-76) years, and most patients were male (86%), Caucasian (96%), and had undergone a transthoracic esophagogastrectomy (74%) for what proved to be a node positive (86%) adenocarcinoma (86%).
  • An earlier pathologic stage was the only predictor for a better outcome.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Cisplatin / administration & dosage. Esophagectomy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Prospective Studies. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19668013.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Hartsell WF, Scott CB, Dundas GS, Mohiuddin M, Meredith RF, Rubin P, Weigensberg IJ: Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03. Am J Clin Oncol; 2007 Aug;30(4):368-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
  • PURPOSE: To identify factors that are predictive of satisfactory acute and long-term pulmonary tolerance of definitive irradiation and, conversely, factors that are predictive of excessive impairment of pulmonary functions.
  • Eligible patients had surgically unresectable or medically inoperable stage II or III non-small cell lung cancer.
  • A quantitative nuclear medicine perfusion study was correlated to the radiation therapy portals to assess the proportion of lung irradiated.
  • Squamous cell carcinoma was the predominant histology and 93% of the patients had AJCC stage III disease.
  • Grade >or=2 acute lung toxicity was seen in 18% of patients; patients least likely to develop lung toxicity are those with undetectable levels of IL-6 at 10 Gy and diffusing capacity of the lung for carbon monoxide percent (DLCO%) >54.
  • Grade >or=2 late lung toxicity was seen in 30% of patients.
  • Karnofsky performance status was the only pretreatment factor predictive of late lung toxicity.
  • The proportion of lung within the irradiated field, BDI indices, physician-assessed baseline dyspnea, and baseline PFT were not predictive of pulmonary toxicity.
  • Using grade >or=2 toxicity as an event, age >60 years, gender, and a surfactant level <797 at 20 Gy were predictive of late lung toxicity.
  • CONCLUSIONS: Elevated levels of serum IL-6 after 10 Gy of lung irradiation appear to predict grade >or=2 acute lung toxicity, and high serum levels of surfactant apoproteins at 20 Gy correlated with grade >or=2 late pulmonary toxicity.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / radiotherapy. Interleukin-6 / blood. Lung Neoplasms / radiotherapy. Radiation Injuries / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / radiotherapy. Carcinoma, Large Cell / blood. Carcinoma, Large Cell / radiotherapy. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / radiotherapy. Female. Humans. Lung / radiation effects. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Radiotherapy Dosage. Respiratory Function Tests. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762437.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-6
  •  go-up   go-down


15. Mack PC, Holland WS, Burich RA, Sangha R, Solis LJ, Li Y, Beckett LA, Lara PN Jr, Davies AM, Gandara DR: EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol; 2009 Dec;4(12):1466-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
  • PURPOSE: Activating mutations in the epidermal growth factor receptor (EGFR) are associated with enhanced response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC), whereas KRAS mutations translate into poor patient outcomes.
  • METHODS: An allele-specific polymerase chain reaction assay using Scorpion-amplification refractory mutation system (DxS, Ltd) was used to detect mutations in plasma DNA from patients with advanced stage NSCLC treated as second- or third-line therapy on a phase I/II trial of docetaxel plus intercalated erlotinib.
  • Four of 49 patients harbored a de novo T790M resistance mutation (median progression-free survival, 3.9 months).

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19884861.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA093373; United States / NCI NIH HHS / CA / P30 CA93373
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Quinazolines; 0 / Taxoids; 15H5577CQD / docetaxel; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


16. Woo T, Okudela K, Yazawa T, Wada N, Ogawa N, Ishiwa N, Tajiri M, Rino Y, Kitamura H, Masuda M: Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. Lung Cancer; 2009 Sep;65(3):355-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas.
  • The purpose of the present study was to establish accurate prognostic markers to predict the post-operative recurrence of stage I lung adenocarcinomas (ADC).
  • One-hundred and ninety cases of stage I ADC were examined for KRAS mutations and Ki-67 expression, and their associations with disease recurrence were analyzed.
  • Ki-67 high-expressers with KRAS mutations showed an additional higher risk of recurrence compared to low-expressers without mutations (5-year DFS 37.5% vs. 93.3%, P<0.001: adjusted HR 16.82, 95% CI 3.77-74.98, P<0.001) and their 5-year DFS was nearly equivalent to that of stage II non-small cell lung cancer (NSCLC) in our facility (37.5% vs. 37.2% for stage II NSCLC, p=0.577).
  • The combined use of KRAS status and Ki-67 expression level could be an excellent prognostic marker to predict the post-operative recurrence of stage I ADC.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Biomarkers, Tumor / metabolism. Ki-67 Antigen / biosynthesis. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. Mutation. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19162366.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRAS protein, human; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


17. Zhao ZL, Song N, Huang QY, Liu YP, Zhao HR: [Clinicopathologic features of lung pleomorphic (spindle/giant cell) carcinoma--a report of 17 cases]. Ai Zheng; 2007 Feb;26(2):183-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic features of lung pleomorphic (spindle/giant cell) carcinoma--a report of 17 cases].
  • BACKGROUND & OBJECTIVE: Lung pleomorphic (spindle/giant cell) carcinoma is a rare epithelial malignant tumor.
  • METHODS: Clinicopathologic records of 17 patients with lung pleomorphic (spindle/giant cell) carcinoma were reviewed and compared with those of the patients with other histopathologic types of lung cancer treated in the same period.
  • RESULTS: The 17 patients consisted of 15 men and 2 women with median age of 58 (45-78)û 5 at stage I, 3 at stage II, and 9 at stage III by pathologic TNM staging.
  • Of the 17 cases of lung pleomorphic (spindle/giant cell) carcinoma, 2 were lung exclusive spindle cell carcinoma, 5 were lung carcinoma with spindle cells (combined with one kind of epithelial components, such as squamous cell carcinoma in 3 cases, adenocarcinoma in 1 case, and large cell carcinoma in 1 case), 10 were lung carcinoma with giant cell carcinoma (combined with one kind of epithelial components in 5 cases, two kinds in another 5 cases).
  • Four patients at stage I survived free of tumor for more than 5 years.
  • The median survival time was significantly shorter in lung pleomorphic (spindle/giant cell) carcinoma patients than in lung squamous cell carcinoma patients (36 months vs. 61 months, P=0.027), and was also significantly longer in patients with carcinoma containing spindle cells (including spindle cell carcinoma) than in patients with carcinoma containing giant cells (64 months vs. 18 months,P=0.026).
  • Lymph node metastasis and carcinoma containing giant cells were poor prognostic factors of lung pleomorphic (spindle/giant cell) carcinoma.
  • CONCLUSION: Lung carcinoma containing giant cells has multiple cells components, and has worse prognosis than lung carcinoma containing spindle cells and spindle cells carcinoma do.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Giant Cell / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pneumonectomy. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17298750.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Belani CP, Schreeder MT, Steis RG, Guidice RA, Marsland TA, Butler EH, Ramalingam SS: Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer; 2008 Nov 01;113(9):2512-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study.
  • BACKGROUND: Cetuximab, an immunoglobulin (Ig) G1 chimeric monoclonal antibody against the epidermal growth factor receptor, has demonstrated evidence of activity in nonsmall cell lung cancer (NSCLC).
  • METHODS: Chemotherapy-naïve patients aged >or=18 years with stage IIIB (with effusion) or stage IV NSCLC received cetuximab (at a dose of 400 mg/m(2) on Day 1 and 250 mg/m(2) on Days 8 and 15) plus docetaxel (at a dose of 75 mg/m(2) on Day 1) and carboplatin (area under the concentration vs time curve [AUC]=6 on Day 1) every 21 days for up to 6 cycles (graded according to the American Joint Committee on Cancer Staging System).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Carboplatin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Cetuximab. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Male. Middle Aged. Prognosis. Remission Induction. Survival Rate. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18816622.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA180864
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; PQX0D8J21J / Cetuximab
  •  go-up   go-down


19. Lin DM, Ma Y, Liu XY, Zheng S, Xue LY, Liu XY, Zou SM, Lü N, He ZG, Liu FS: [Prognostic significance of micropapillary pattern in pulmonary adenocarcinoma]. Zhonghua Bing Li Xue Za Zhi; 2006 Mar;35(3):151-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic significance of micropapillary pattern in pulmonary adenocarcinoma].
  • OBJECTIVE: To evaluate the prognostic significance of micropapillary pattern (MPP) in adenocarcinoma of lung.
  • METHODS: Ninety-one consecutively excised cases of pulmonary adenocarcinoma, including follow-up data, were retrospectively studied.
  • The 5-year survival rates were 88.9% for stage I tumors, 46.2% for stage II tumors, and 23.8% for stage III tumor respectively (P = 0.000).
  • The extent of micropapillary component showed no correlation with tumor stage, size and 5-year survival rate (P = 0.065, 0.358 and 0.206, respectively).
  • In pulmonary adenocarcinoma, this characteristic histology correlated with tumor stage and size, but not with patient's gender and smoking history.
  • Within the same stage, the 5-year survival rates of MPP-positive and MPP-negative groups were as follows: for stage I, 78.6% versus 92.6% (P = 0.1548), for stage II, 30.0% versus 100% (P = 0.0598), and for stage III, 17.7% versus 28.6% (P = 0.4045).
  • CONCLUSIONS: MPP in primary pulmonary adenocarcinoma, even when only constituting a minor component, predicts an aggressive clinical behavior and is associated with poor prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Papillary / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Adult. Aged. Female. Follow-Up Studies. Humans. Lung / pathology. Lung / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630503.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Chang JW, Asamura H, Kawachi R, Watanabe S: Gender difference in survival of resected non-small cell lung cancer: histology-related phenomenon? J Thorac Cardiovasc Surg; 2009 Apr;137(4):807-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender difference in survival of resected non-small cell lung cancer: histology-related phenomenon?
  • OBJECTIVE: It remains controversial whether there is a gender difference in survival of patients with resected non-small cell lung cancer.
  • METHODS: We retrospectively analyzed 2770 patients (1689 men and 1081 women) with non-small cell lung cancer who underwent pulmonary resection between 1995 and 2005 at the National Cancer Center Hospital, Tokyo.
  • A gender difference in survival was studied in all patients, in those divided according to histology or pathologic stage, and in propensity-matched gender pairs.
  • The proportions of adenocarcinoma and pathologic stage I in women were greater than those in men (93.6% vs 61.7% and 71.4% vs 58.6%, respectively) (P < .001).
  • In adenocarcinoma, the overall 5-year survival for women was better than that for men in pathologic stage I (95% vs 87%, P < .001) and in pathologic stage II or higher (58% vs 51%, P = .017).
  • In non-adenocarcinoma, there was no significant gender difference in survival in pathologic stage I (P = .313) or pathologic stage II or higher (P = .770).
  • The variables such as age, smoking status, histology, and pathologic stage were used for propensity score matching, and survival analysis of propensity score-matched gender pairs did not show a significant difference (P = .69).
  • A gender difference in survival was observed only in the adenocarcinoma subset, suggesting pathobiology in adenocarcinoma in women might be different from that of men.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / mortality. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19327500.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. LeCaer H, Delhoume JY, Thomas PA, Berard H, Paillotin D, Barriere JR, Gimenez C, Vergnenegre A, Muller P, Auquier P, Perol M: Multicenter phase II trial of carboplatin/vinorelbine in elderly patients with advanced non-small-cell lung cancer efficacy and impact on quality of life: Groupe Francais de Pneumo-Cancerologie Study 9902. Clin Lung Cancer; 2005 Sep;7(2):114-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter phase II trial of carboplatin/vinorelbine in elderly patients with advanced non-small-cell lung cancer efficacy and impact on quality of life: Groupe Francais de Pneumo-Cancerologie Study 9902.
  • BACKGROUND: Approximately 30% of lung cancer cases are diagnosed in patients > 70 years of age.
  • We conducted a multicenter phase II trial to determine the efficacy and safety of carboplatin combined with vinorelbine every 4 weeks as first-line treatment for advanced non-small-cell lung cancer (NSCLC) in elderly patients.
  • PATIENTS AND METHODS: Patients were eligible if they were aged >OR= 70 years, had stage IIIB (with pleural effusion) or stage IV NSCLC, had a performance status of 0/1, had not previously received chemotherapy, and had normal organ function.
  • Eighty percent of patients had stage IV NSCLC, with squamous cell (n=21), adenocarcinoma (n=12), and undifferentiated (n=7) histologies.
  • CONCLUSION: Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quality of Life

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179098.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; BG3F62OND5 / Carboplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


22. Detterbeck FC, Socinski MA, Gralla RJ, Edelman MJ, Jahan TM, Loesch DM, Limentani SA, Govindan R, Zaman MB, Ye Z, Monberg MJ, Obasaju CK: Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer. J Thorac Oncol; 2008 Jan;3(1):37-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer.
  • BACKGROUND: Surgical resection alone remains suboptimal for patients with early-stage (I or II) non-small cell lung cancer.
  • Two similar randomized phase II trials were conducted to define an active preoperative regimen in this disease state.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Cisplatin / administration & dosage. Drug Administration Schedule. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166839.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC, Chen KY, Lin ZZ, Huang CJ, Shun CT, Huang CL, Bean J, Cheng AL, Pao W, Yang PC: Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol; 2008 Jun 1;26(16):2745-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.
  • PURPOSE: To explore predictive factors for time to treatment failure (TTF) in chemotherapy-naive non-small-cell lung cancer (NSCLC) patients receiving gefitinib treatment.
  • PATIENTS AND METHODS: We designed a phase II study to test gefitinib antitumor efficacy in advanced-stage, chemotherapy-naive NSCLC patients.
  • In multivariate analysis, the presence of EGFR deletion exon 19 or L858R EGFR mutations in adenocarcinoma patients predicted longer TTF.
  • CONCLUSION: In this prospective study, EGFR exon 19 deletion or L858R mutations in adenocarcinoma were the best predictors for longer TTF in stage IIIB/IV chemotherapy-naive NSCLC patients receiving first-line gefitinib monotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Genes, erbB-1 / genetics. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use


24. Zhou ZW, Wan DS, Wang GQ, Ren JQ, Lu ZH, Lin SX, Tang SX, Ye YL, Chen G: [Inhibitory effect of angiogenesis inhibitor YH-16 on liver metastases from colorectal cancer]. Ai Zheng; 2006 Jul;25(7):818-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: YH-16, a new recombinant angiogenesis inhibitor, has demonstrated synergetic effects with chemotherapy in non-small-cell lung cancer treatment in stage II clinical trial.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Animals. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Endothelial Cells / cytology. Female. Inhibitory Concentration 50. Mice. Mice, Inbred BALB C. Microvessels / pathology. Random Allocation. Tumor Burden / drug effects

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831270.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Endostatins; 0 / Vascular Endothelial Growth Factor A; 0 / vascular endothelial growth factor A, mouse
  •  go-up   go-down


25. Kim AW, Faber LP, Warren WH, Shah ND, Basu S, Liptay MJ: Bilobectomy for non-small cell lung cancer: a search for clinical factors that may affect perioperative morbidity and long-term survival. J Thorac Cardiovasc Surg; 2010 Mar;139(3):606-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilobectomy for non-small cell lung cancer: a search for clinical factors that may affect perioperative morbidity and long-term survival.
  • OBJECTIVE: The resection of two lobes for non-small cell lung cancer has the potential for significant morbidity and mortality as well as a negative impact on survival.
  • METHODS: Age, gender, diagnosis, bilobectomy type, bilobectomy indication, operative technique, pathologic condition, major complications, stage, and survival were reviewed from 1984 through 2007.
  • RESULTS: Bilobectomies were performed on 92 patients with non-small cell lung cancer.
  • Significant differences in survival were observed among the different stages (stage I, 65%; stage II, 42%; stage III, 13%; P < .0001).
  • When bilobectomy was performed for extension across the fissure, survival approached significance for squamous cell carcinomas (71%) over adenocarcinomas (42%) by log-rank test (P < .089) and was significant by likelihood ratio (P < .048) when comparing survival between adenocarcinoma and squamous cell carcinoma.
  • Multivariate analysis demonstrated that increasing age (P = .0102) and upper&middle bilobectomy (P = .0285) adversely affected 5-year survival, whereas early-stage disease (P = .0245) beneficially affected 5-year survival.
  • Survival relates to disease stage.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / mortality. Lung Neoplasms / surgery. Pneumonectomy / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 The American Association for Thoracic Surgery. All rights reserved.
  • (PMID = 19709677.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Elayadi AN, Samli KN, Prudkin L, Liu YH, Bian A, Xie XJ, Wistuba II, Roth JA, McGuire MJ, Brown KC: A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res; 2007 Jun 15;67(12):5889-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer.
  • The development of new modes of diagnosis and targeted therapy for lung cancer is dependent on the identification of unique cell surface features on cancer cells and isolation of reagents that bind with high affinity and specificity to these biomarkers.
  • We recently isolated a 20-mer peptide which binds to the lung adenocarcinoma cell line, H2009, from a phage-displayed peptide library.
  • We show here that the cellular receptor for this peptide, TP H2009.1, is the uniquely expressed integrin, alphavbeta6, and the peptide binding to lung cancer cell lines correlates to integrin expression.
  • Expression of alphavbeta6 was assessed on 311 human lung cancer samples.
  • The expression of this integrin is widespread in early-stage nonsmall cell lung carcinoma (NSCLC).
  • Preferential expression is observed in the tumors compared with the surrounding normal lung tissue.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575158.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HV / N01-HV-28185; United States / NCI NIH HHS / CA / P50CA70907; United States / NCI NIH HHS / CA / R01 CA106646; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / 1 R01 CA 106646-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Integrins; 0 / Peptide Library; 0 / Peptides; 0 / integrin alphavbeta6
  •  go-up   go-down


27. Oxnard GR, Fidias P, Muzikansky A, Sequist LV: Non-small cell lung cancer in octogenarians: treatment practices and preferences. J Thorac Oncol; 2007 Nov;2(11):1029-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-small cell lung cancer in octogenarians: treatment practices and preferences.
  • INTRODUCTION: Among patients with non-small cell lung cancer (NSCLC), patients aged 80 or older have inferior survival.
  • Patient treatment regimens were evaluated for consistency with contemporaneous stage-specific guideline-recommended therapy (GRT).
  • RESULTS: Patients characteristics included median age of 82.6 years (range, 80-92), 30% stage I-II, 39% stage IV, 59% performance status 0-1, 25% performance status >or=2 (performance status unavailable for 15%).
  • Of 70 patients with stage III or IV disease, 36% received cytotoxic chemotherapy and 27% received oral targeted therapy alone.
  • Thirty-two percent of patients received the stage-specific GRT.
  • CONCLUSIONS: The vast majority of octogenarian patients with NSCLC receive antineoplastic therapy, but only one third of this population receives stage-specific GRT.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / therapy. Age Distribution. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / therapy. Female. Humans. Male. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17975495.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Hirsh V, Soulieres D, Duclos M, Faria S, Del Vecchio P, Ofiara L, Ayoub JP, Charpentier D, Gruber J, Portelance L, Souhami L: Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer. J Thorac Oncol; 2007 Oct;2(10):927-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
  • INTRODUCTION: The optimal combination of concomitant radiotherapy (RT) and chemotherapy in stage III unresectable non-small cell lung cancer (NSCLC) remains unclear.
  • The role of induction chemotherapy with carboplatin/gemcitabine regimen has not been established in stage III NSCLC.
  • METHODS: Forty-two stage III NSCLC patients, 41 assessable, with a median age of 60 years and good performance status, entered this trial between January 2003 and November 2004.
  • The median survival was 25 months, the 1-year survival rate was 73.2%, and the 2-year survival rate was 50.5%.
  • Further studies using this approach are warranted in patients with stage III NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Carboplatin / administration & dosage. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dose-Response Relationship, Drug. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Prospective Studies. Radiotherapy Dosage. Remission Induction. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909355.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


29. Kadara H, Lacroix L, Behrens C, Solis L, Gu X, Lee JJ, Tahara E, Lotan D, Hong WK, Wistuba II, Lotan R: Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila); 2009 Aug;2(8):702-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system.
  • Lung cancer continues to be a major deadly malignancy.
  • We hypothesized that genes differentially expressed among cells constituting an in vitro human lung carcinogenesis model consisting of normal, immortalized, transformed, and tumorigenic bronchial epithelial cells are relevant to the clinical outcome of non-small cell lung cancer (NSCLC).
  • A subset of these genes (n = 584) separated lung adenocarcinoma clinical samples (n = 361) into two clusters with significant survival differences.
  • The mRNA and protein levels of one these genes-UBE2C-were significantly up-regulated in NSCLC tissue relative to normal lung and increased progressively in lung lesions.
  • Moreover, stage I NSCLC patients with positive UBE2C expression exhibited significantly poorer overall and progression-free survival than patients with negative expression.
  • Our studies with this in vitro model have lead to the identification of a robust six-gene signature, which may be valuable for predicting the survival of lung adenocarcinoma patients.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2001 Jun 7;20(26):3348-53 [11423985.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6014-22 [18829480.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] BMC Cancer. 2001;1:6 [11472637.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):165-9 [12582028.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4167-73 [12874022.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] Cancer Res. 1988 Apr 1;48(7):1904-9 [2450641.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6693-7 [1323115.001]
  • [Cites] Cancer Res. 1996 May 1;56(9):2224-8 [8616876.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1580-6 [9362155.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11891-6 [9751761.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):791-800 [10213214.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1317-21 [10433621.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9027-34 [15604268.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):232-41 [15671551.001]
  • [Cites] Breast Cancer Res. 2005;7(4):171-9 [15987472.001]
  • [Cites] Bioinformatics. 2005 Sep 1;21(17):3524-9 [16081476.001]
  • [Cites] Oncogene. 2005 Nov 21;24(52):7729-45 [16299533.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1121-7 [16489064.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):214-24 [16698281.001]
  • [Cites] Cancer Biol Ther. 2006 Jun;5(6):665-73 [16775421.001]
  • [Cites] Respirology. 2006 Sep;11(5):533-8 [16916324.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11194-206 [17145864.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4259-66 [11709570.001]
  • [Cites] Semin Surg Oncol. 2000 Mar;18(2):106-15 [10657912.001]
  • [Cites] Eur Respir J. 2000 Mar;15(3):547-52 [10759451.001]
  • [Cites] Neoplasia. 2006 Dec;8(12):1062-71 [17217624.001]
  • [Cites] Mol Cell Biol. 2007 Apr;27(8):3176-86 [17283043.001]
  • [Cites] Nature. 2007 Apr 19;446(7138):876-81 [17443180.001]
  • [Cites] Nature. 2007 Apr 19;446(7138):921-5 [17443186.001]
  • [Cites] Nat Rev Genet. 2007 Aug;8(8):601-9 [17607306.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8065-80 [17804718.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] J Clin Invest. 2007 Oct;117(10):2740-50 [17909619.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):564-70 [18385730.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):32-40 [18398830.001]
  • [Cites] Nat Med. 2008 Aug;14(8):822-7 [18641660.001]
  • [Cites] BMC Cancer. 2008;8:238 [18702824.001]
  • [Cites] N Engl J Med. 2008 Sep 25;359(13):1367-80 [18815398.001]
  • [CommentIn] Cancer Prev Res (Phila). 2009 Aug;2(8):695-7 [19638487.001]
  • (PMID = 19638491.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA70907; United States / NCI NIH HHS / CA / P50 CA070907-10; United States / NCI NIH HHS / CA / P30 CA 16672; United States / NCI NIH HHS / CA / P50 CA070907-09; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / UO1 CA86390; United States / NCI NIH HHS / CA / P50 CA070907-11; United States / NCI NIH HHS / CA / U01 CA086390
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 6.3.2.19 / UBE2C protein, human; EC 6.3.2.19 / Ubiquitin-Conjugating Enzymes
  • [Other-IDs] NLM/ NIHMS383276; NLM/ PMC3382104
  •  go-up   go-down


30. Sousa M, Cavadas S, Moreira MJ, Mellidez JC: Long survival with erlotinib as second line treatment in non-small cell lung cancer. Rev Port Pneumol; 2008 Oct;14 Suppl 3:S85-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long survival with erlotinib as second line treatment in non-small cell lung cancer.
  • [Transliterated title] Longa sobrevida com erlotinib como tratamento de segunda linha do cancro do pulmão de não pequenas células.
  • The pleural liquid study, the bronchofiberscope examination, the biopsy and the studies for cancer staging allowed the diagnosis: Lung Adenocarcinoma stage IIIB (positive pleural effusion) - December 2005.
  • He maintains the same treatment with disease stability and a general good condition, only showing a grade II rash (face, forearms and hands) as secondary effect of treatment.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 Sociedade Portuguesa de Pneumologia/SPP.
  • (PMID = 25967693.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Lung cancer / Neoplasia do pulmão / adenocarcinoma / carboplatin / erlotinib / gemcitabine / primeira linha de tratamento / tratamento com erlotinib
  •  go-up   go-down


31. Lee YC, Wu CT, Kuo SW, Tseng YT, Chang YL: Significance of extranodal extension of regional lymph nodes in surgically resected non-small cell lung cancer. Chest; 2007 Apr;131(4):993-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of extranodal extension of regional lymph nodes in surgically resected non-small cell lung cancer.
  • STUDY OBJECTIVES: Regional lymph node (LN) involvement affects the prognosis of patients with surgically resected non-small cell lung cancer (NSCLC).
  • The relationships between extranodal extension and histologic type, grade of differentiation, vascular invasion, tumor size, pathologic stage, p53 expression, or patient survival were analyzed.
  • RESULTS: Extranodal extension was significantly higher in women, adenocarcinoma, advanced stage, tumors with vascular invasion, or p53 overexpression.
  • The total number and positive rate of resected LNs with extranodal extension were significantly correlated with advanced stage, tumors with vascular invasion, or p53 overexpression.
  • By multivariate analysis of survival, the presence or total number of LNs with extranodal extension, tumor stage, and p53 expression were significant prognostic factors.
  • The 5-year survival rate of stage IIIA patients without extranodal extension (30.4%) was significantly better than that of stage II patients with extranodal extension (16.8%).
  • No survival difference between extranodal positive stage II and IIIA patients was noted.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Lymph Node Excision / methods


32. Sakai M, Oguri T, Sato S, Hattori N, Bessho Y, Achiwa H, Maeda H, Niimi T, Ueda R: Spontaneous hepatic rupture due to metastatic tumor of lung adenocarcinoma. Intern Med; 2005 Jan;44(1):50-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous hepatic rupture due to metastatic tumor of lung adenocarcinoma.
  • A 64-year-old man diagnosed as lung adenocarcinoma with hepatic tumor was admitted to our hospital.
  • He carried the hepatitis B virus but was negative for PIVKA-II and alpha-fetoprotein, and hence we diagnosed a case of stage IV lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Liver Diseases / etiology. Liver Neoplasms / complications. Liver Neoplasms / secondary. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15704663.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


33. Lustberg MB, Bekaii-Saab T, Young D, Otterson G, Burak W, Abbas A, McCracken-Bussa B, Lustberg ME, Villalona-Calero MA: Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol; 2010 May;5(5):713-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.
  • BACKGROUND: Based on the observation of topoisomerase-1, upregulation by mitomycin C (MMC), and the phase I antitumor activity of sequential MMC/irinotecan in esophageal cancer, we conducted a phase II evaluation of two schedules of this combination in previously untreated stage III/IV esophageal/gastroesophageal junction adenocarcinomas.
  • A two-stage Simon minimax design was used for each arm, with a "pick-the-winner" approach based on efficacy.
  • CONCLUSION: Irinotecan/MMC is feasible in esophageal/gastroesophageal junction adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):289-300 [9748633.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 May;63(6):1073-82 [18795290.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] Control Clin Trials. 1999 Aug;20(4):343-52 [10440561.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):659-68 [16129366.001]
  • [Cites] Ann Thorac Surg. 2006 Mar;81(3):1076-81 [16488726.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1086-92 [18309943.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(13):1773-82 [10673991.001]
  • [Cites] Hum Pathol. 2000 Jun;31(6):631-2 [10872653.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] Ann Oncol. 2002 Dec;13(12):1841-51 [12453851.001]
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):428-32 [12560430.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Science. 1989 Nov 24;246(4933):1046-8 [2555920.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5919-24 [2168285.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] Mol Pharmacol. 1995 May;47(5):907-14 [7538195.001]
  • [Cites] Biochemistry. 1996 May 7;35(18):5778-86 [8639538.001]
  • [Cites] Ann N Y Acad Sci. 1996 Dec 13;803:74-92 [8993502.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):161-7 [9219702.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4551-6 [18574157.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • (PMID = 20354452.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA16059; United States / NCI NIH HHS / CA / R21 CA092956; United States / NCRR NIH HHS / RR / UL1 RR025755; United States / NCI NIH HHS / CA / K12 CA133250; United States / NCI NIH HHS / CA / P30 CA016059; United States / NCI NIH HHS / CA / R21CA92956
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS460376; NLM/ PMC3641556
  •  go-up   go-down


34. Linnerth NM, Sirbovan K, Moorehead RA: Use of a transgenic mouse model to identify markers of human lung tumors. Int J Cancer; 2005 May 10;114(6):977-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a transgenic mouse model to identify markers of human lung tumors.
  • Lung cancer remains the leading cause of cancer related deaths worldwide.
  • Despite advances in detection technologies, most patients diagnosed with lung cancer already harbor metastatic lesions.
  • Because early detection is one of the primary determinants of patient outcome, a transgenic mouse model of lung cancer was utilized to identify markers of early lung tumors in humans.
  • DNA microarray analysis of lung tumors arising in MMTV-IGF-II transgenic mice showed 9 genes consistently elevated in the murine lung tumors.
  • Western blot analyses confirmed that several of these proteins were elevated in the lung tumors and immunohistochemical analyses identified 3 proteins, microsomal glutathione-S-transferase 1 (Mgst1), cathepsin H and syndecan 1 as being consistently elevated in the murine lung tumors compared to non-tumor bearing transgenic lung tissue and normal lung tissue surrounding the tumor.
  • These 3 proteins were also elevated in human lung adenocarcinoma and squamous cell carcinomas.
  • Importantly, the proteins were elevated in early stage, node negative tumors indicating their ability to detect early lung lesions that would be amenable to surgical resection.
  • Therefore, our findings indicate that Mgst1, cathepsin H and syndecan 1 should be further evaluated as markers capable of identifying patients with early stage lung tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / pathology. Disease Models, Animal. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Mice, Transgenic

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15645424.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Sdc1 protein, mouse; 0 / Syndecan-1; 0 / Syndecans; EC 2.5.1.- / microsomal glutathione S-transferase-I; EC 2.5.1.18 / Glutathione Transferase; EC 3.4.- / Cathepsins; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.16 / CTSH protein, human; EC 3.4.22.16 / Cathepsin H; EC 3.4.22.16 / Ctsh protein, mouse
  •  go-up   go-down


35. Shivapurkar N, Stastny V, Suzuki M, Wistuba II, Li L, Zheng Y, Feng Z, Hol B, Prinsen C, Thunnissen FB, Gazdar AF: Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett; 2007 Mar 8;247(1):56-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of a methylation gene panel by quantitative PCR for lung cancers.
  • Detection of lung cancer at early stages could potentially increase survival rates.
  • One promising approach is the application of suitable lung cancer-specific biomarkers to specimens obtained by non-invasive methods.
  • Using quantitative real time PCR, we tested 11 genes (3-OST-2, RASSF1A, DcR1, DcR2, P16, DAPK, APC, ECAD, HCAD, SOCS1, SOCS3) for levels of methylation within their promoter sequences in non-small cell lung cancers (NSCLC), adjacent non-malignant lung tissues, in peripheral blood mononuclear cells (PBMC) from cancer free patients, in sputum of cancer patients and controls.
  • 3-OST-2 followed by, RASSF1A showed increased levels of methylation with advanced tumor stage (P<0.05).

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Top Microbiol Immunol. 2000;249:35-54 [10802937.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6493-8 [10829066.001]
  • [Cites] Annu Rev Biochem. 1999;68:729-77 [10872465.001]
  • [Cites] J Cell Sci. 2000 Aug;113 ( Pt 16):2813-9 [10910765.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4366-71 [10969779.001]
  • [Cites] Bioessays. 2001 Apr;23(4):352-8 [11268041.001]
  • [Cites] Oncogene. 2001 Jun 14;20(27):3528-32 [11429699.001]
  • [Cites] Br J Radiol. 2001 Jun;74(882):478-85 [11459725.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18 Suppl):83S-86S [11560979.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):371-5 [11809682.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):210-9 [11990857.001]
  • [Cites] Annu Rev Biochem. 2002;71:435-71 [12045103.001]
  • [Cites] Cytometry. 2002 Jun 15;50(3):168-76 [12116340.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):629-34 [12163387.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):420-30 [12189384.001]
  • [Cites] Eur Respir J. 2002 Aug;20(2):464-79 [12212983.001]
  • [Cites] Oncogene. 2003 Jan 16;22(2):274-80 [12527896.001]
  • [Cites] Nat Cell Biol. 2003 Mar;5(3):190-2 [12646874.001]
  • [Cites] Histol Histopathol. 2003 Apr;18(2):665-77 [12647816.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1370-5 [12684406.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3034-41 [12912953.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14133-8 [14617776.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):786-92 [14999791.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2284-8 [15073103.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2928-35 [15131027.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3757-60 [15172980.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4244-50 [15205337.001]
  • [Cites] Clin Lung Cancer. 2004 May;5(6):366-70 [15217536.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):619-27 [8573335.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1197-206 [9508208.001]
  • [Cites] Curr Opin Cell Biol. 1999 Apr;11(2):255-60 [10209153.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 21;91(8):675-90 [10218505.001]
  • [Cites] Oncogene. 2005 Jan 20;24(4):732-6 [15580314.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Int J Cancer. 2005 Sep 10;116(4):656-60 [15825171.001]
  • (PMID = 16644104.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA096109; United States / NCI NIH HHS / CA / P50 CA070907-079001; United States / NCI NIH HHS / CA / CA070907-070003; United States / NCI NIH HHS / CA / P50 CA70907; United States / NCI NIH HHS / CA / CA070907-060003; United States / NCI NIH HHS / CA / P50 CA070907-060003; United States / NCI NIH HHS / CA / U01 CA084971; United States / NCI NIH HHS / CA / P50 CA070907-070003; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / P50 CA070907-069001; United States / NCI NIH HHS / CA / P01 CA096964; United States / NCI NIH HHS / CA / CA070907-079001; United States / NCI NIH HHS / CA / CA070907-069001
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS191864; NLM/ PMC3379713
  •  go-up   go-down


36. Akerley W, Boucher KM, Bentz JS, Arbogast K, Walters T: A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer. J Thorac Oncol; 2009 Feb;4(2):214-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.
  • INTRODUCTION: Erlotinib improves survival in patients with advanced non-small cell lung cancer who have been previously treated with systemic chemotherapy.
  • METHODS: Eligibility criteria included stage IIIB/IV or recurrent non-small cell lung cancer, no prior chemotherapy for systemic disease, performance status = 0 to 1, no history of brain metastases, and weight loss less than 10%.
  • Histologies were adenocarcinoma in 22 and squamous cell in six.
  • CONCLUSIONS: Despite a modest response rate, lack of enrichment for never-smokers and absence of conventional chemotherapy in many patients, the median and long-term survivals were comparable with those expected after conventional sequencing of chemotherapy.
  • Erlotinib as initial therapy was well tolerated and warrants randomized evaluation as first-line treatment for advanced lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Erlotinib Hydrochloride. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179899.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


37. Goldin-Lang P, Tran QV, Fichtner I, Eisenreich A, Antoniak S, Schulze K, Coupland SE, Poller W, Schultheiss HP, Rauch U: Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep; 2008 Jul;20(1):123-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis.
  • Non-small cell lung cancer (NSCLC) comprises of 75% of all lung cancers.
  • The TF protein concentration was quantified by ELISA in a subset of 11 AC and 9 normal tissue specimens as well as in the plasma of 13 lung cancer patients and 15 healthy controls.
  • AsHTF mRNA expression was significantly lower in patients with stage IA disease compared to patients with higher grade stages, pointing to TF as being a marker of malignancy and metastases.
  • TF protein of lung tumors was significantly increased in AC (p=0.004 vs. controls).
  • TF in plasma was up-regulated in lung cancer patients (334.9+/-95.4 vs. 124.1+/-14.8 pg/ml; p=0.02 vs. controls).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / chemistry. Lung Neoplasms / chemistry. Thromboplastin / analysis. Thrombosis / etiology
  • [MeSH-minor] Adenocarcinoma / chemistry. Blotting, Western. Humans. Immunohistochemistry. Neoplasm Metastasis. RNA, Messenger / analysis


38. Martoni AA, Melotti B, Sperandi F, Giaquinta S, Piana E, Pavesi L, Da Prada G, Lelli G: Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study. Lung Cancer; 2008 Jun;60(3):387-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study.
  • /oral (hybrid) administration of vinorelbine (VNR) plus cisplatin (CDDP), followed by oral VNR, could result in a more suitable first-line regimen for patients (pts) with advanced non-small cell lung cancer (aNSCLC) in the outpatient setting.
  • RESULTS: Fifty-three pts entered the study: 80% males; median age 63 years (range 43-71); median ECOG PS 0 (range 0-1); histotype: adenocarcinoma 59%, epidermoid 31%, undifferentiated 10%; disease stage: IIIB 22%, IV 70%, recurrent disease 8%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / administration & dosage. Lung Neoplasms / drug therapy. Vinblastine / analogs & derivatives


39. Lu P, Yu L, Li Y, Sun Y: A correlation study between maximum standardized uptake values and pathology and clinical staging in nonsmall cell lung cancer. Nucl Med Commun; 2010 Jul;31(7):646-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A correlation study between maximum standardized uptake values and pathology and clinical staging in nonsmall cell lung cancer.
  • OBJECTIVE: To investigate the relationship between maximum standardized uptake value and pathological type, degree of differentiation, tumor size, and clinical staging of nonsmall cell lung cancer (NSCLC).
  • RESULTS: There was a significant correlation between the SUVmax of NSCLC and the pathological type (r= 0.391, P= 0.000); the SUVmax of squamous cell carcinoma (SCC) was higher than that of adenocarcinoma (AC) (P =0.000), and the SUVmax of AC was higher than that of bronchioloalveolar carcinoma (P = 0.004).
  • The SUVmax of AC had a positive correlation with clinical staging (r= 0.298, P = 0.006); SUVmax was lower in stage I than in stages II, III, and IV (P = 0.047, 0.038 and 0.015, respectively); however, the SUVmax in stages II, III, and IV were not different (P= 0.708, 0.570 and 0.528, respectively).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / metabolism. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Biological Transport. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Differentiation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Tumor Burden

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wolters Kluwer Health / Lippincott Williams & Wilkins.
  • (PMID = 20545045.001).
  • [ISSN] 1473-5628
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


40. Wang QS, Li M, Zhang LY, Jin Y, Tong DD, Yu Y, Bai J, Huang Q, Liu FL, Liu A, Lee KY, Fu SB: Down-regulation of ING4 is associated with initiation and progression of lung cancer. Histopathology; 2010 Aug;57(2):271-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of ING4 is associated with initiation and progression of lung cancer.
  • ING4 inhibition has been reported in various tumours, including gliomas, breast tumours, and stomach adenocarcinoma.
  • The aim was to evaluate ING4 expression in lung cancers.
  • METHOD AND RESULTS: By immunohistochemistry of 246 lung tumour tissues, reduced ING4 nuclear and cytoplasmic expression were both revealed in lung cancer and associated with tumour grade.
  • Nuclear ING4 inhibition correlated with the tumour stage and lymph node metastasis.
  • Furthermore, ING4 expression was lower in grade III than in grades I-II tumours.
  • CONCLUSIONS: Our results indicate that overall inhibition of ING4 expression and ING4 expression higher in cytoplasm than in nucleus of tumour cells may be involved in the initiation and progression of lung cancers, and thus, analysis for ING4 expression may be useful as a clinical diagnostic and prognostic tool for lung cancer.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Cycle. 2005 Sep;4(9):1153-6 [16096374.001]
  • [Cites] Gene. 2005 Aug 15;356:109-17 [15935570.001]
  • [Cites] Exp Cell Res. 2006 Apr 15;312(7):951-61 [16516887.001]
  • [Cites] J Biol Chem. 2006 Nov 10;281(45):34677-86 [16973615.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2552-8 [17363573.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4111-6 [17634537.001]
  • [Cites] Oncogene. 2007 Aug 9;26(36):5247-57 [17325660.001]
  • [Cites] Trends Biochem Sci. 2007 Nov;32(11):509-19 [17949986.001]
  • [Cites] Cancer Sci. 2008 Jan;99(1):23-30 [17956589.001]
  • [Cites] Cancer Sci. 2008 Mar;99(3):531-8 [18081876.001]
  • [Cites] Int J Cancer. 2008 Oct 1;123(7):1483-90 [18636562.001]
  • [Cites] Carcinogenesis. 2008 Jul;29(7):1373-9 [18375955.001]
  • [Cites] Mol Cell Biol. 2008 Nov;28(21):6632-45 [18779315.001]
  • [Cites] Cancer Lett. 2008 Nov 18;271(1):105-16 [18789575.001]
  • [Cites] Exp Cell Res. 2008 Oct 15;314(17):3130-41 [18775696.001]
  • [Cites] Respir Res. 2009;10:14 [19250543.001]
  • [Cites] J Pathol. 2009 Sep;219(1):87-95 [19479822.001]
  • [Cites] Semin Oncol. 2001 Apr;28(2 Suppl 4):3-13 [11479891.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9671-6 [11481424.001]
  • [Cites] Histopathology. 2002 Apr;40(4):360-6 [11943021.001]
  • [Cites] Oncogene. 2003 Jan 23;22(3):343-50 [12545155.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2373-8 [12750254.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4926-34 [14581367.001]
  • [Cites] Nature. 2004 Mar 18;428(6980):328-32 [15029197.001]
  • [Cites] Pathologe. 1987 May;8(3):138-40 [3303008.001]
  • [Cites] Nat Genet. 1996 Dec;14(4):415-20 [8944021.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16251-6 [15528276.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):243-50 [15668501.001]
  • [Cites] Int J Biochem Cell Biol. 2005 May;37(5):1054-65 [15743678.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 17;331(4):1032-8 [15882981.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7481-6 [15897452.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6450-8 [16024650.001]
  • [Cites] Oncol Rep. 2006 Mar;15(3):545-9 [16465410.001]
  • (PMID = 20716169.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] ENG
  • [Grant] None / None / / 82788-1; Canada / Canadian Institutes of Health Research / / 82788-1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA Primers; 0 / Homeodomain Proteins; 0 / ING4 protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ CAMS3768; NLM/ PMC3855453
  •  go-up   go-down


41. Spigel DR, Greco FA, Thompson DS, Webb C, Rubinsak J, Inhorn RC, Reeves J Jr, Vazquez ER, Lane CM, Burris HA 3rd, Hainsworth JD: Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer. Clin Lung Cancer; 2010 May;11(3):198-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer.
  • BACKGROUND: Targeting epidermal growth factor receptors (EGFRs) has been a novel strategy in treating non-small-cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: Eligibility criteria were newly diagnosed unresectable stage III/IV NSCLC, all histologies, measurable disease, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2.
  • Patients had a median age of 69 years; 70% were male and 30% were female; ECOG PS was 0 in 42%, 1 in 51%, and 2 in 7%; patients had adenocarcinoma (42%), squamous cell (30%), large cell (6%), mixed (1%), and not otherwise specified (20%) disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20439197.001).
  • [ISSN] 1938-0690
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; PQX0D8J21J / Cetuximab
  •  go-up   go-down


42. Cicenas S, Vencevicius V: Lung cancer in patients with tuberculosis. World J Surg Oncol; 2007;5:22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer in patients with tuberculosis.
  • BACKGROUND: Coexistent lung cancer and pulmonary tuberculosis is an urgent problem of thoracic surgery presenting a challenging task for diagnosis and surgical treatment.
  • MATERIALS AND METHODS: From 1990 to 2005, 2218 patients with lung cancer underwent surgical treatment in Department of Thoracic Surgery and Oncology, Institute of Oncology, Vilnius University.
  • In 46 (2.1%) patients coexistence of lung cancer and tuberculosis was found.
  • Central lung cancer was diagnosed in 37 (80.4%) and peripheral--in 9 (19.6%) patients.
  • Epidermoid cancer was diagnosed in 24 (52.2%) patients, adenocarcinoma--in 10 (21.7%) and adenoepidermoid carcinoma--in 12 (26.1%) patients.
  • Stage I cancer was diagnosed in 12 (26.1%), stage II--in 11 (23.9%), and stage IIIA--in 23 (50%) patients.
  • CONCLUSION: Coexistence of tuberculosis and lung cancer in thoracic surgery is fairly rare.
  • This combination was diagnosed only in 46 cases (2.1%) out of 2218 operated lung cancer patients.
  • Epidermoid carcinoma and stage IIIA disease was diagnosed in 50% of patients.
  • Postoperative surgical complications occurred in 9 patients (19.5%) with lung cancer and tuberculosis.
  • Surgery is the method of choice in treatment of combination of tuberculosis and lung cancer.
  • [MeSH-major] Lung Neoplasms / epidemiology. Lung Neoplasms / therapy. Pneumonectomy / methods. Tuberculosis, Pulmonary / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kekkaku. 1999 Feb;74(2):157-62 [10191612.001]
  • [Cites] Probl Tuberk. 1984 Aug;(8):55-8 [6238330.001]
  • [Cites] Arkh Patol. 1986;48(3):52-60 [3010915.001]
  • [Cites] Probl Tuberk. 1989;(6):26-9? [2771907.001]
  • [Cites] J Postgrad Med. 1991 Oct;37(4):185-9 [1841965.001]
  • [Cites] Jpn J Clin Oncol. 1993 Aug;23(4):205-20 [8411734.001]
  • [Cites] Chest. 1994 Feb;105(2):514-9 [7905815.001]
  • [Cites] Kekkaku. 1999 Nov;74(11):797-802 [10599212.001]
  • [Cites] Am J Epidemiol. 1995 Jun 1;141(11):1023-32 [7771438.001]
  • (PMID = 17309797.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1805441
  • [General-notes] NLM/ Original DateCompleted: 20070810
  •  go-up   go-down


43. Clément-Duchêne C, Krupitskaya Y, Ganjoo K, Lavori P, McMillan A, Kumar A, Zhao G, Padda S, Zhou L, Pedro-Salcedo MS, Colevas AD, Wakelee HA: A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer. J Thorac Oncol; 2010 Nov;5(11):1821-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.
  • BACKGROUND: Bevacizumab improves responses and progression-free survival when added to first-line paclitaxel/carboplatin or cisplatin/gemcitabine for patients with advanced nonsquamous non-small cell lung cancer.
  • METHODS: Patients with untreated advanced nonsquamous non-small cell lung cancer, with no evidence of brain metastases and not on anticoagulation were eligible.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3284-9 [19433684.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3217-24 [19433683.001]
  • [Cites] Future Oncol. 2009 Dec;5(10):1545-53 [20001795.001]
  • [Cites] Ann Oncol. 2010 Sep;21(9):1804-9 [20150572.001]
  • [Cites] Lung Cancer. 2010 Dec;70(3):340-6 [20347506.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 9):50-4 [12094340.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):242-7 [12562651.001]
  • [Cites] Eur J Cancer. 1996 Feb;32A(2):243-8 [8664035.001]
  • [Cites] Lung Cancer. 2005 Jan;47(1):69-80 [15603856.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):142-53 [15625369.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8380-8 [16293868.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] J Thorac Oncol. 2008 May;3(5):511-5 [18449004.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 May;8(5):689-99 [18471042.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3543-51 [18506025.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4617-25 [18678835.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1227-34 [19188680.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • (PMID = 20881641.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA124435; United States / NCRR NIH HHS / RR / UL1 RR025744; United States / NCATS NIH HHS / TR / UL1 TR001085
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ NIHMS637070; NLM/ PMC4241413
  •  go-up   go-down


44. Kurup A, Lin C-, Murry DJ, Dobrolecki L, Estes D, Yiannoutsos CT, Mariano L, Sidor C, Hickey R, Hanna N: Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. Ann Oncol; 2006 Jan;17(1):97-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University.
  • This study combined rhAngiostatin with a standard chemotherapy regimen in patients with advanced non-small-cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: Eligible patients had chemotherapy-naïve stage IIIB (with pleural effusion) or IV NSCLC, performance status (PS) 0 or 1, no history of bleeding, brain metastasis or requirements for anti-coagulation.
  • RESULTS: Patient characteristics (n = 24) were: 16 males, median age 66 years (range 45-78), 54% PS 1, 83.3% stage IV and 62.5% adenocarcinoma.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282244.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 86090-08-6 / Angiostatins; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


45. Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R, Vokes EE: Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol; 2008 Sep;3(9):1003-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
  • INTRODUCTION: This Phase I trial aimed to determine the maximum-tolerated-dose of erlotinib administered with two standard chemoradiotherapy regimens for non-small cell lung cancer.
  • METHODS: Unresectable stage III non-small cell lung cancer patients were enrolled in this 2-arm dose-escalation study.
  • PATIENT CHARACTERISTICS: performance status 0 to 24 patients, 1 to 10 patients, median age 63 years, adenocarcinoma 21% and female 14 patients.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758303.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009566-15; United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / P30 CA14599-32; United States / NCI NIH HHS / CA / CA009566-15; United States / NCI NIH HHS / CM / N01 CM007003; United States / NCI NIH HHS / CM / N01 CM-07003-74; United States / NCI NIH HHS / CA / T32 CA009566
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / Taxoids; 15H5577CQD / docetaxel; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS154299; NLM/ PMC4535721
  •  go-up   go-down


46. Bruzzi JF, Truong M, Zinner R, Erasmus JJ, Sabloff B, Munden R: Short-term restaging of patients with non-small cell lung cancer receiving chemotherapy. J Thorac Oncol; 2006 Jun;1(5):425-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-term restaging of patients with non-small cell lung cancer receiving chemotherapy.
  • OBJECTIVE: To determine whether computed tomography (CT) performed within a month of receiving chemotherapy is useful in assessing response among patients with non-small cell lung cancer (NSCLC).
  • Tumor histology included adenocarcinoma (n = 30), squamous cell carcinoma (n = 17), and NSCLC otherwise unspecified (n = 10).
  • Clinical tumor, node, metastasis stage was stage II (n = 2), stage III (n = 11), and stage IV (n = 44).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409894.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


47. Solis LM, Raso MG, Kalhor N, Behrens C, Wistuba II, Moran CA: Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases. Am J Clin Pathol; 2010 Jan;133(1):133-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases.
  • Sixteen cases of primary oncocytic adenocarcinomas of the lung are reported.
  • Surgical staging disclosed 14 patients (88%) with stage I disease, 1 (6%) with stage II, and 1 (6%) with stage III.
  • These cases represent an unusual variant of pulmonary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Oxyphil Cells / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. DNA Mutational Analysis. DNA, Neoplasm / analysis. Fatal Outcome. Female. Humans. Lung / pathology. Lung / surgery. Male. Middle Aged. Mutation. Neoplasm Recurrence, Local. Neoplasm Staging. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20023269.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


48. Schütte W, Nagel S, Schaedlich S, Brust D, Blankenburg T: Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program. Onkologie; 2005 Apr;28(4):195-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program.
  • BACKGROUND: The molecular genesis of lung cancer and its treatment remain hot spots of medical research because of the high mortality rates especially associated with non-small-cell lung cancer (NSCLC).
  • Adenocarcinoma histology and former nicotine abstention seem to favor sensitivity to gefitinib.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Palliative Care / methods. Quinazolines / administration & dosage. Risk Assessment / methods. Terminal Care / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15840967.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


49. Yan S, Shun-Chang J, Li C, Jie L, Ya-Li L, Ling-Xiong W: Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer. BMC Cancer; 2010;10:621
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer.
  • BACKGROUND: Adjuvant chemotherapy has been shown to improve survival rates of postoperative patients with non-small cell lung cancer (NSCLC).
  • The objective of this study was to explore the possible prognostic and predictive role of topoisomerase II alpha (TopIIα) expression level in postoperative NSCLC patients who received adjuvant chemotherapy.
  • METHODS: Patients with stage I-III NSCLC, who underwent surgery in our hospital from January 2004 to December 2007 and who also received adjuvant chemotherapy after surgery, were analyzed in this study.
  • Univariate survival analysis showed that male sex (P = 0.036), non-adenocarcinoma (P = 0.004), earlier pathological TNM stage (P = 0.001) or pathological N stage (P < 0.001), and high expression of TopIIα (P = 0.012) were correlated with better DFS, whereas age, smoking history, different chemotherapy regimens, T stage and expression level of Ki67 were of no prognostic significance.
  • COX multivariate analysis showed that pathological TNM stage, histological subtype and expression level of TopIIα to be independent of risk factors affecting DFS in postoperative NSCLC patients who received chemotherapy.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / enzymology. Carcinoma, Non-Small-Cell Lung / surgery. Chemotherapy, Adjuvant / methods. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Lung Neoplasms / drug therapy. Lung Neoplasms / enzymology. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1999;10 Suppl 5:S83-6 [10582146.001]
  • [Cites] J Cancer Res Clin Oncol. 2010 Jul;136(7):1029-37 [20052594.001]
  • [Cites] Lung Cancer. 2001 May;32(2):117-28 [11325482.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2A):905-10 [11396183.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):235-43 [12067686.001]
  • [Cites] Int J Oncol. 2004 Jan;24(1):201-9 [14654958.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3965-70 [14666704.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):351-60 [14736927.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3860-7 [15326194.001]
  • [Cites] Cancer Res. 1987 Oct 15;47(20):5455-60 [2888532.001]
  • [Cites] J Natl Cancer Inst. 1992 Jan 15;84(2):113-8 [1310509.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7):1666-74 [1312895.001]
  • [Cites] Br J Cancer. 1993 Mar;67(3):456-63 [8382508.001]
  • [Cites] Biochim Biophys Acta. 1995 Dec 27;1264(3):337-46 [8547322.001]
  • [Cites] Br J Cancer. 1996 Dec;74(12):1869-76 [8980384.001]
  • [Cites] Breast Cancer Res Treat. 1999 May;55(1):61-71 [10472780.001]
  • [Cites] J Clin Oncol. 2005 May 10;23(14):3270-8 [15886314.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R374-84 [15987433.001]
  • [Cites] Mol Pharmacol. 2005 Sep;68(3):625-34 [15942022.001]
  • [Cites] Lancet Oncol. 2006 Sep;7(9):719-27 [16945766.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):994-9 [17289895.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2893-8 [17363613.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):736-44 [18258981.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] BMC Cancer. 2009;9:72 [19250538.001]
  • [Cites] Lancet Oncol. 2009 Oct;10(10):1001-10 [19796752.001]
  • [Cites] Ann Surg Oncol. 2010 May;17(5):1392-7 [20217261.001]
  • [Cites] Future Oncol. 2010 May;6(5):741-67 [20465389.001]
  • [Cites] Pathobiology. 2000 May-Jun;68(3):137-43 [11174071.001]
  • (PMID = 21067592.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2988758
  •  go-up   go-down


50. Movsas B, Langer CJ, Ross HJ, Wang L, Jotte RM, Feigenberg S, Xu F, Huang CH, Monberg MJ, Obasaju CK: Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer. J Thorac Oncol; 2010 May;5(5):673-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer.
  • PURPOSE: Southwest Oncology Group 9504 demonstrated the feasibility and potential benefit of docetaxel consolidation after etoposide, cisplatin, and radiotherapy in patients with locally advanced non-small cell lung cancer.
  • METHODS: Patients with stage III non-small cell lung cancer and good performance status were included.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / therapy. Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Squamous Cell / therapy. Lung Neoplasms / therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20354453.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


51. Biswas S, Sarkar S, Chakraborty J, Chakrabarti S: Occult micrometastasis to bone marrow in early lung cancer: a clinicopathologic study from West Bengal, India. Asian Pac J Cancer Prev; 2010;11(3):747-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult micrometastasis to bone marrow in early lung cancer: a clinicopathologic study from West Bengal, India.
  • Although bone marrow micrometastasis may remain silent, its detection changes the staging and management of lung cancer.
  • In the present study conducted in West Bengal, India, 74 diagnosed bronchogenic carcinoma cases (28 squamous cell carcinomas, 20 adenocarcinomas, 9 small cell carcinomas, 4 large cell carcinomas, 13 unclassified) in early stages (stage I, II and IIIA) were included.
  • We detected marrow metastasis in 44.4% cases of small cell carcinomas and 21.2% cases of non small cell lung cancer (50% of large cell carcinomas, 20% of adenocarcinomas, 17.9% of squamous cell carcinomas) and 15.4% cases of unclassified carcinoma.
  • A definite correlation noted between micrometastasis with the clinical stage (no case in Stage I, 12.5% in Stage II, 30.4% in Stage IIIA patients).
  • [MeSH-major] Adenocarcinoma / secondary. Bone Marrow Neoplasms / secondary. Carcinoma, Large Cell / secondary. Carcinoma, Small Cell / secondary. Carcinoma, Squamous Cell / secondary. Lung Neoplasms / pathology


52. Preis M, Korc M: Kinase signaling pathways as targets for intervention in pancreatic cancer. Cancer Biol Ther; 2010 May 15;9(10):754-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer related mortality in the United States.
  • The prognosis of patients with PDAC is extremely poor with a median survival of 6 months, in part due to the advanced stage at the time of diagnosis and early metastatic spread.
  • The relatively recent introduction of novel therapies targeting tyrosine kinase and serine/threonine kinase pathways have yielded dramatic results in certain hematological malignancies, and have resulted in significant advances in our ability to treat patients with melanoma, breast, lung and colon cancer, thereby leading to improved survival and quality of life.
  • Thus, despite encouraging phase I/II studies, the vast majority of phase-III studies have failed to demonstrate improved efficacy in PDAC.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20234186.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-R37-75059
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hedgehog Proteins; EC 2.7.- / Phosphotransferases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


53. Kubota K, Nishiwaki Y, Tamura T, Nakagawa K, Matsui K, Watanabe K, Hida T, Kawahara M, Katakami N, Takeda K, Yokoyama A, Noda K, Fukuoka M, Saijo N: Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol; 2008 Dec;3(12):1439-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.
  • INTRODUCTION: The aim of this study was to evaluate the efficacy and safety of Erlotinib in Japanese patients with previously treated non-small cell lung cancer (NSCLC).
  • METHODS: This open-label phase II trial enrolled stage III/IV NSCLC patients who had progressive disease after at least one prior platinum-based chemotherapy regimen.
  • Three patients who had deletion mutations on exon 19 (del E746-A750 or del S752-I759) exhibited objective response.
  • Four patients (6%) experienced interstitial lung disease-like events, one of whom died.
  • The toxicity profile was similar to that in Western patients, except for a somewhat higher incidence of skin disorders and interstitial lung disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Salvage Therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Asian Continental Ancestry Group. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Disease-Free Survival. Erlotinib Hydrochloride. Female. Humans. Male. Middle Aged. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19057270.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


54. Oshita F, Saito H, Murakami S, Kondo T, Yamada K: Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer. Am J Clin Oncol; 2010 Feb;33(1):66-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer.
  • OBJECTIVES: We conducted a phase II study of combination chemotherapy with paclitaxel (Pac) and irinotecan (CPT) alternating with gefitinib (Gef) to determine the qualitative and quantitative toxicities and efficacy of this combination against advanced non-small-cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: Patients with stage IIIB or IV NSCLC were treated with CPT at 60 mg/m2 and Pac at 160 mg/m2 on day 1 followed by Gef at 250 mg per day on days 8 to 14 every 3 weeks.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19786849.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 7673326042 / irinotecan; P88XT4IS4D / Paclitaxel; S65743JHBS / gefitinib; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


55. Kaira K, Takise A, Minato K, Iwasaki Y, Ishihara S, Takei Y, Tsuchiya S, Saito R, Sato K, Mori M: Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer. Anticancer Drugs; 2005 Apr;16(4):455-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer.
  • We conducted a phase II study to examine the efficacy and safety of weekly docetaxel and cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC).
  • Forty chemotherapy-naive patients (10 with stage IIIB and 30 with stage IV NSCLC) with an Eastern Cooperative Oncology Group performance status of 0-2 and adequate organ functions were enrolled.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Cisplatin / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Survival Rate. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746583.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


56. Jacot W, Lhermitte L, Dossat N, Pujol JL, Molinari N, Daurès JP, Maudelonde T, Mangé A, Solassol J: Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes. J Thorac Oncol; 2008 Aug;3(8):840-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes.
  • HYPOTHESIS: Lung cancer remains the leading cause of cancer-related mortality worldwide.
  • Currently known serum markers do not efficiently diagnose lung cancer at early stage.
  • METHODS: In the present study, we developed a serum proteomic fingerprinting approach coupled with a three-step classification method to address two important clinical questions: (i) to determine whether or not proteomic profiling differs between lung cancer and benign lung diseases in a population of smokers and (ii) to assess the prognostic impact of this profiling in lung cancer.
  • Proteomic spectra were obtained from 170 pathologically confirmed lung cancer or smoking patients with benign chronic lung disease serum samples.
  • RESULTS: Among the 228 protein peaks differentially expressed in the whole population, 88 differed significantly between lung cancer patients and benign lung disease, with area under the curve diagnostic values ranging from 0.63 to 0.84.
  • Multiprotein classifiers based on differentially expressed peaks allowed the classification of lung cancer and benign disease with an area under the curve ranging from 0.991 to 0.994.
  • Using a cross-validation methodology, diagnostic accuracy was 93.1% (sensitivity 94.3%, specificity 85.9%), and more than 90% of the stage I/II lung cancers were correctly classified.
  • Finally, in the prognosis part of the study, a 4628 Da protein was found to be significantly and independently associated with prognosis in advanced stage non-small cell lung cancer patients (p = 0.0005).
  • CONCLUSIONS: The potential markers that we identified through proteomic fingerprinting could accurately classify lung cancers in a high-risk population and predict survival in a non-small cell lung cancer population.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. Lung Neoplasms / blood. Proteome / analysis
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / classification. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Carcinoma, Large Cell / classification. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / classification. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / secondary. DNA Fingerprinting / methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Proteomics / methods. ROC Curve. Risk Factors. Small Cell Lung Carcinoma / classification. Small Cell Lung Carcinoma / diagnosis. Small Cell Lung Carcinoma / secondary. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670301.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome
  •  go-up   go-down


57. Babiak A, Hetzel J, Godde F, König HH, Pietsch M, Hetzel M: Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC--a phase II trial. Br J Cancer; 2007 Apr 10;96(7):1052-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC--a phase II trial.
  • Single-agent therapy with Docetaxel or Pemetrexed is the current therapy of choice for second-line treatment in advanced non-small-cell lung cancer (NSCLC).
  • Forty-two patients (stage IIIB and IV, pretreated with platinum-based chemotherapy) received 8 mg m(-2) Mitomycin C on day 1 and 25 mg m(-2) Vinorelbine on days 1 and 8 of a 28-day cycle.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R940-52 [16280040.001]
  • [Cites] Curr Oncol Rep. 2000 Jan;2(1):96-101 [11122830.001]
  • [Cites] Curr Treat Options Oncol. 2002 Feb;3(1):53-8 [12057087.001]
  • [Cites] Lung Cancer. 2004 Feb;43(2):183-94 [14739039.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):1000-4 [14647419.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1589-97 [15117980.001]
  • [Cites] Cancer Treat Rep. 1984 Nov;68(11):1325-9 [6388831.001]
  • [Cites] Chest. 1985 Mar;87(3):368-72 [2982552.001]
  • [Cites] Cancer Treat Rep. 1985 Sep;69(9):945-51 [2992785.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):886-91 [2159054.001]
  • [Cites] Semin Oncol. 1991 Apr;18(2 Suppl 4):42-8 [1851577.001]
  • [Cites] Am J Clin Oncol. 1991 Oct;14(5):405-11 [1659174.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1866-72 [8410111.001]
  • [Cites] Tumori. 1994 Feb 28;80(1):33-6 [8191595.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):645-51 [7884425.001]
  • [Cites] BMJ. 1995 Oct 7;311(7010):899-909 [7580546.001]
  • [Cites] Oncology. 1996 Jan-Feb;53(1):16-8 [8570125.001]
  • [Cites] CA Cancer J Clin. 1998 Jan-Feb;48(1):6-29 [9449931.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7508-15 [16243825.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2354-62 [10856094.001]
  • (PMID = 17353918.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ PMC2360135
  •  go-up   go-down


58. Yu JH, Wei Q, Qi FJ, Xu HT, Wang EH: [Significance of caveolin-1 expression in primary lung cancer]. Zhonghua Bing Li Xue Za Zhi; 2006 Nov;35(11):664-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance of caveolin-1 expression in primary lung cancer].
  • OBJECTIVE: To study the expression of caveolin-1 in primary lung cancer and its relationship with microvessel density and clinicopathologic parameters.
  • METHODS: Immunohistochemical study for caveolin-1 and CD34 was performed on paraffin sections of 154 cases of primary lung cancer and adjacent non-neoplastic lung parenchymal tissue, as well as 36 cases with nodal metastasis.
  • Western blot assay was also employed in tumor and non-neoplastic lung tissues of the 50 cases (25 cases of pulmonary squamous cell carcinoma and 25 cases of pulmonary adenocarcinoma) with fresh specimens available.
  • The expression rate of caveolin-1 in lung cancer was 59.1%, which was significantly lower than that in normal lung tissues (P < 0.01).
  • Western blot assay confirmed that the expression of caveolin-1 in pulmonary squamous cell carcinoma and adenocarcinoma was lower than in surrounding non-neoplastic lung tissues (P < 0.01).
  • The expression was also higher in stage III and IV than in stage I and II disease (P = 0.042).
  • CONCLUSIONS: The expression of caveolin-1 is lower in lung cancer tissues than that in non-small cell carcinoma, it is also significantly correlated with tumor stage and lymph node metastasis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Caveolin 1 / biosynthesis. Lung Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Blotting, Western. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Humans. Immunohistochemistry. Lung / chemistry. Lung / metabolism. Lung / pathology. Lymphatic Metastasis. Male. Microvessels / chemistry. Microvessels / metabolism. Microvessels / pathology. Middle Aged. Neoplasm Staging. Small Cell Lung Carcinoma / metabolism. Small Cell Lung Carcinoma / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374210.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Caveolin 1
  •  go-up   go-down


59. Nyman J, Friesland S, Hallqvist A, Seke M, Bergström S, Thaning L, Lödén B, Sederholm C, Wagenius G: How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group. Lung Cancer; 2009 Jul;65(1):62-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group.
  • BACKGROUND: A combination of chemotherapy and radiotherapy is the treatment base for locally advanced non-small cell lung cancer (NSCLC).
  • Attempts to improve the loco-regional control were made in three separate phase II studies in Swedish University Hospitals, where accelerated radiotherapy or concurrent daily or weekly chemotherapy with conventional radiotherapy were tested.
  • Comparatively good results from these studies lead to this national randomized phase II study, the RAKET-study, where the different concepts were investigated on a wider basis for further phase III studies.
  • METHODS: Inoperable stage III non-small cell lung cancer patients in good performance status (PS<2) were equally randomized to either of three arms in eight institutions.
  • Thirty-four percent had stage IIIa and 66% IIIb.
  • HISTOLOGY: adenocarcinoma 48%, squamous cell carcinoma 32% and 20% non-small cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19081652.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


60. Dong QM, Zheng WH, He YJ: [Comparison of the clinicopathological characteristics of colorectal cancer between elderly and young patients]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Sep;30(9):2128-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The elderly patients were more likely to have stage II and III tumors than the middle-aged and young patients, having also significantly higher incidences of such complications as heart and lung diseases upon diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20855269.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


61. Rossi D, Dennetta D, Ugolini M, Catalano V, Alessandroni P, Giordani P, Baldelli AM, Casadei V, Graziano F, Luzi Fedeli S: Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial. Target Oncol; 2010 Dec;5(4):231-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial.
  • Efficacy of this drug was documented in the BR.21 trial showing that adenocarcinoma, female gender, Asian ethnicity and never-smoker status are predictive of clinical response to erlotinib.
  • The trial included 31 patients with pretreated stage IIIB (2) and IV (29) non-small cell lung cancer (NSCLC).
  • Even though this trial does not allow us to draw a definitive conclusion about the role of a particular clinical characteristic predictive of response, the "clinical benefit" was documented especially in females, in patients with adenocarcinoma histology and skin rash, confirming previous retrospective data.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Aged. Aged, 80 and over. Erlotinib Hydrochloride. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Male. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Sex Factors. Smoking / adverse effects. Tumor Stem Cell Assay

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3543-51 [18506025.001]
  • [Cites] Lancet. 2008 Nov 22;372(9652):1809-18 [19027483.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3159-67 [10880430.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2350-7 [18467727.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1589-97 [15117980.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2061-7 [10615079.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2354-62 [10856094.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4405-11 [16983108.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 5;95(5):362-72 [12618501.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):190-6 [15625373.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1383-9 [12663731.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Lung Cancer. 2008 Oct;62(1):78-84 [18423781.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 6;91(1):66-72 [9890172.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4663-9 [17925563.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Chest. 2005 Aug;128(2):947-57 [16100191.001]
  • (PMID = 20890670.001).
  • [ISSN] 1776-260X
  • [Journal-full-title] Targeted oncology
  • [ISO-abbreviation] Target Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; Adenocarcinoma of lung
  •  go-up   go-down


62. Wu C, Hao H, Li L, Zhou X, Guo Z, Zhang L, Zhang X, Zhong W, Guo H, Bremner RM, Lin P: Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol; 2009 Jan;4(1):30-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients.
  • BACKGROUND: Enumeration of circulating tumor cells (CTCs) may be valuable for lung cancer treatment and monitoring cancer patient relapse.
  • In the present study we report clinical significance of lung cancer CTC.
  • METHODS: CTCs were enriched from peripheral blood of 47 lung cancer patients by means of a modified enrichment strategy, followed by identification with immunofluorescence staining using anticytokeratins 18 and 19 monoclonal antibodies.
  • Among 41 newly diagnosed and 6 recurrent lung cancer patients (3 stage I-II, 22 stage III and 22 stage IV) including 27 adenocarcinoma (ADC), 7 squamous cell carcinoma and 13 small cell lung cancer (SCLC), positive detection rate of newly diagnosed patients with CTC >/=2/7.5 ml blood was 78% (ADC stage III), 75% (squamous cell carcinoma stage III) and 60% (SCLC stage III), respectively.
  • Whereas 46% (ADC IV) and 71% (SCLC IV) were observed for stage IV patients.
  • CONCLUSIONS: Results of the present study suggest potential clinical utilities of CTC enumeration on lung cancer patients in terms of rapid evaluation of chemotherapy effect in real time and monitoring lung cancer recurrence.
  • A large scale of study which is necessary for further validation of the significance of lung cancer CTC is being performed.
  • [MeSH-major] Biomarkers, Tumor / blood. Lung Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplastic Cells, Circulating / pathology. Small Cell Lung Carcinoma / pathology
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antibodies, Monoclonal. Carcinoma, Large Cell / blood. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Case-Control Studies. Follow-Up Studies. Humans. Immunoenzyme Techniques. Keratin-18 / blood. Prognosis. Sensitivity and Specificity. Tuberculosis, Pulmonary / blood. Tuberculosis, Pulmonary / pathology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096303.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Keratin-18
  •  go-up   go-down


63. Kasprzyk M, Dyszkiewicz W, Zwaruń D, Leśniewska K, Wiktorowicz K: [The assessment of acute phase proteins as prognostic factors in patients surgically treated for non-small cell lung cancer]. Pneumonol Alergol Pol; 2008;76(5):321-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The assessment of acute phase proteins as prognostic factors in patients surgically treated for non-small cell lung cancer].
  • INTRODUCTION: The aim of the study was to assess quantitative changes of the acute phase protein (APP) serum level in patients with non-small cell lung cancer (NSCLC) who underwent a radical resection.
  • We analysed the correlation between quantitative APP changes and: the survival rate, the histological type of the cancer, TNM stage and grading.
  • The most frequent histological types of cancer were: squamous cell lung cancer (24 patients) and adenocarcinoma (17 patients).
  • The majority of them were in stage II B (15 patients) and III A (14 patients).
  • RESULTS: The level of AT was significantly higher in patients with adenocarcinoma, as compared to other histological types of cancer.
  • In the case of patients with squamous cell lung cancer, significantly higher M and Cp.
  • The multivariate analysis confirmed the influence of the following factors on long-term survival: N stage, histological type of cancer and preoperative serum levels of AGP and Hp.
  • CONCLUSIONS: The serum concentration of some APP may correlate with the more aggressive clinical behavior of lung cancer.
  • The patients with N1 or N2 stage of adenocarcinoma have significantly higher serum level of AT and the preoperative concentration of AGP and Hp correlates with the overall survival.
  • [MeSH-major] Acute-Phase Proteins / analysis. Adenocarcinoma / blood. Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Squamous Cell / blood. Lung Neoplasms / blood


64. Niang A, Bonnichon A, Ba-Fall K, Dussart C, Camara P, Vaylet F, Mbaye PS, L'Her P, Sane M, Margery J: [Lung cancer in Senegal]. Med Trop (Mars); 2007 Dec;67(6):651-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung cancer in Senegal].
  • In Africa the incidence of lung cancer is rising rapidly.
  • The purpose of this prospective study was to analyze clinical, therapeutic, and prognostic features of lung cancer patients treated at the Principal Hospital in Dakar between 2002 and 2007.
  • The histological diagnosis was squamous cell carcinoma in 23 cases, adenocarcinoma in 14, large-cell carcinoma in 17, small-cell lung cancer in 2, and bronchiolo-alveolar cancer in 1.
  • Tumor staging demonstrated grades I-II in 6 cases, grade II in 17, and grade IV in 49.
  • Prognosis of the disease is poor because management is undertaken at an advanced stage.
  • Lung cancer is a health issue in Dakar, Senegal.
  • [MeSH-major] Carcinoma / epidemiology. Carcinoma / therapy. Lung Neoplasms / epidemiology. Lung Neoplasms / therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300532.001).
  • [ISSN] 0025-682X
  • [Journal-full-title] Médecine tropicale : revue du Corps de santé colonial
  • [ISO-abbreviation] Med Trop (Mars)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


65. Agarwala A, Fisher W, Bruetman D, McClean J, Taber D, Titzer M, Juliar B, Yu M, Breen T, Einhorn LH, Hanna N: Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group. J Thorac Oncol; 2008 Apr;3(4):374-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
  • BACKGROUND: Gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) pathway, has single agent activity in non-small cell lung cancer (NSCLC).
  • METHODS: chemotherapy-naive, stage IIIb (with pleural effusion) or IV NSCLC, Eastern Cooperative Oncology Group Performance Status (PS) 0-1.
  • RESULTS: From January 2004 to November 2004, 31 patients were enrolled: male/female 13/18; median age 70 years (range, 19-93); 68% had adenocarcinoma; Eastern Cooperative Oncology Group PS 0/1 13/18; stage IIIb/IV 2/29.
  • Two patients died of interstitial lung disease due to treatment.
  • All responders were females with adenocarcinoma, two were remote or never smokers and three were former smokers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Celecoxib. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pyrazoles / administration & dosage. Quinazolines / administration & dosage. Sulfonamides / administration & dosage. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379355.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Quinazolines; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib; S65743JHBS / gefitinib
  •  go-up   go-down


66. Tibaldi C, Bernardini I, Chella A, Russo F, Vasile E, Malventi M, Falcone A: Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer; 2006 May;7(6):401-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer.
  • PURPOSE: In patients with advanced-stage non-small-cell lung cancer (NSCLC) pretreated with chemotherapy, docetaxel 75 mg/m2 every 3 weeks prolongs survival compared with best supportive care alone or chemotherapy with ifosfamide or vinorelbine.
  • PATIENTS AND METHODS: Thirty-three elderly patients (aged > or = 70 years) with advanced-stage NSCLC, Eastern Cooperative Oncology Group performance status 0-2, and a median age of 74 years (range, 70-83 years) who had progressed after 1 line of chemotherapy were treated with docetaxel 37.5 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 courses.
  • CONCLUSION: Our modified schedule of docetaxel is an active and well-tolerated second-line treatment in elderly patients with advanced-stage NSCLC and has a favorable toxicity profile.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Taxoids / administration & dosage
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Drug Administration Schedule. Female. Health Services for the Aged. Humans. Italy. Male. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800966.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


67. Ruan YH, Hua HR, Gao Q, Song JL, Liang R, Jin KW: [Pathological study of lung cancer induced by Yunnan tin mine dusts in F344 rats]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2007 Jun;25(6):331-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathological study of lung cancer induced by Yunnan tin mine dusts in F344 rats].
  • OBJECTIVE: To set up animal models of the lung cancer induced by Yunnan tin mineral dusts (no radon) in F344 rats and to explore the process of carcinogenesis and pathologic alterations in various stages of malignant transformation in the animal models.
  • Pollak stein was used to evaluate the development of fibrosis of lung in the rats.
  • RESULTS: Bronchoalveolar inflammation occurred in the early stage after the intratracheal instillation of Yunnan tin mineral dust was performed in F344 rates.
  • Lung cancer was induced in the end.
  • Among the 14 cases of lung cancer, 9 cases were adenocarcinoma, 2 squamous cell carcinoma and 3 mixed carcinoma.
  • No lung cancer occurred in other three control groups.
  • Lung fibrosis was found in 31 cases of in the tin mineral dust group.
  • CONCLUSION: Yunnan tin mineral dusts without radon induce lung cancer in rates.
  • The adenocarcinoma and squamous carcinomas induced in F344 rat lung can occur in the alveoli.
  • The further study on whether type II alveolar epithelial cells are the origin cells of adenocarcinoma and some peripheral squamous lung carcinomas is worthwhile.
  • [MeSH-major] Lung Neoplasms / pathology. Tin / adverse effects
  • [MeSH-minor] Animals. Disease Models, Animal. Dust. Female. Lung / drug effects. Lung / pathology. Male. Rats. Rats, Inbred F344

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17723188.001).
  • [ISSN] 1001-9391
  • [Journal-full-title] Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases
  • [ISO-abbreviation] Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Dust; 7440-31-5 / Tin
  •  go-up   go-down


68. Wang CL, Yue DS, Zhang ZF, Zhan ZL, Sun LN: [Value of thyroid transcription factor-1 in identification of the prognosis of bronchioloalveolar carcinoma]. Zhonghua Yi Xue Za Zhi; 2007 Sep 4;87(33):2350-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Compared with that in the BAC of stage III and that of BAC of non-mucinous type, the CK20 positive rates of the BAC of stage I - II and mucinous type were both significantly higher (chi(2) = 3.928, P < 0.05, and chi(2) = 11.512, P < 0.05).
  • The TTF-1 positive rates of the BAC of stage III and nonmucinous type were significantly higher than those of stage I - II and mucinous type respectively (chi(2) = 7.840, P < 0.05, and chi(2) = 19.497, P < 0.05).
  • Univariate analysis showed that the main prognostic factors were TTF-1 expression (P = 0.017), clinical stage (P = 0.000), tumor diameter (P = 0.017) and N stage (P = 0.000).
  • Strata analysis suggested that in the nonmucinous type BAC patients the survival time of those positive for TTF-1 expression was superior to those negative for TTF-1 (P = 0.009); and in the stage III BAC patients the survival time of those positive for TTF-1 was superior to those negative for TTF-1 (P = 0.022).
  • Cox regression analysis suggested that TTF-1 (P = 0.035), TNM stage (P = 0.000), tumor diameter (P = 0.034), and N stage (P = 0.000) were independent factors affecting the prognosis.
  • TTF-1, TNM stage, tumor diameter and N stage are all independent factors affecting the prognosis of BAC.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Lung Neoplasms / metabolism. Nuclear Proteins / biosynthesis. Transcription Factors / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Keratin-20 / biosynthesis. Keratin-7 / biosynthesis. Lung / chemistry. Lung / pathology. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18036300.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


69. Kunitoh H, Kato H, Tsuboi M, Asamura H, Tada H, Nagai K, Mitsudomi T, Koike T, Nakagawa K, Ichinose Y, Okada M, Shibata T, Saijo N, JCOG Lung Cancer Surgical Study Group: A randomised phase II trial of preoperative chemotherapy of cisplatin-docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer results of a Japan Clinical Oncology Group trial (JCOG 0204). Br J Cancer; 2008 Sep 16;99(6):852-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomised phase II trial of preoperative chemotherapy of cisplatin-docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer results of a Japan Clinical Oncology Group trial (JCOG 0204).
  • Preoperative chemotherapy is a promising strategy in patients with early-stage resectable non-small-cell lung cancer (NSCLC); optimal chemotherapy remains unclear.
  • Clinical (c-) stage IB/II NSCLC patients were randomised to receive either two cycles of docetaxel (D)-cisplatin (P) combination chemotherapy (D 60 mg m(-2) and P 80 mg m(-2) on day 1) every 3-4 weeks or three cycles of D monotherapy (70 mg m(-2)) every 3weeks.
  • Preoperative DP was associated with encouraging resection rate and DFS data, and phase III trials for c-stage IB/II NSCLC are warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Cisplatin / administration & dosage. Disease-Free Survival. Female. Humans. Japan. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Survival Rate. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):247-53 [11773176.001]
  • [Cites] J Thorac Cardiovasc Surg. 2000 Mar;119(3):429-39 [10694600.001]
  • [Cites] Ann Oncol. 2003 Jan;14(1):116-22 [12488303.001]
  • [Cites] Curr Oncol Rep. 2003 Jul;5(4):307-8 [12781072.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2500-7 [12815135.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3016-24 [12837811.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):254-61 [14722033.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):351-60 [14736927.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2602-9 [15226327.001]
  • [Cites] JAMA. 2004 Jul 28;292(4):470-84 [15280345.001]
  • [Cites] Ann Thorac Surg. 2004 Sep;78(3):1017-23; discussion 1017-23 [15337041.001]
  • [Cites] Cancer Treat Rep. 1985 Dec;69(12):1375-81 [4075313.001]
  • [Cites] N Engl J Med. 1994 Jan 20;330(3):153-8 [8043059.001]
  • [Cites] J Natl Cancer Inst. 1994 May 4;86(9):673-80 [8158698.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1232-7 [7911159.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1238-44 [7911160.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1649-55 [8622084.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1948-53 [9586914.001]
  • [Cites] J Clin Oncol. 2005 May 10;23(14):3270-8 [15886314.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5011s-5016s [16000605.001]
  • [Cites] Radiology. 2005 Sep;236(3):1011-9 [16014441.001]
  • [Cites] Lung Cancer. 2005 Nov;50(2):227-34 [16061304.001]
  • [Cites] Br J Cancer. 2006 Apr 24;94(8):1099-106 [16622435.001]
  • [Cites] Lancet Oncol. 2006 Sep;7(9):719-27 [16945766.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Lung Cancer. 2002 Dec;38(3):217-27 [12445742.001]
  • (PMID = 18728643.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2538761
  • [Investigator] Kondo T; Sakurada A; Matsuguma H; Akiyama H; Nagai K; Yoshida J; Saijo N; Asamura H; Suzuki K; Kunitoh H; Goya T; Koshiishi Y; Kato H; Tsuboi M; Nakagawa K; Satoh Y; Watanabe K; Nitadori J; Koike T; Yamato Y; Mitsudomi T; Mori S; Kodama K; Higashiyama M; Ota M; Tada H; Yamamoto R; Okada M; Yoshimura M; Iwanaga K; Yamashita M; Ichinose Y; Yamazaki K; Nagayasu T; Tagawa T
  •  go-up   go-down


70. Nosotti M, Tosi D, Palleschi A, Rosso L, Mendogni P, Santambrogio L: Immunocytochemical detection of occult tumor cells in the bone marrow: prognostic impact on early stages of lung cancer. Eur Surg Res; 2008;41(3):267-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemical detection of occult tumor cells in the bone marrow: prognostic impact on early stages of lung cancer.
  • OBJECTIVES: This study was designed to verify the prognostic impact of occult tumor cells in the bone marrow of stage I and II non-small-cell lung cancer patients using cytokeratin as a micrometastatic marker.
  • METHODS: One hundred and fifty-two patients with stage I and II non-small-cell lung cancer, who underwent radical surgery by pulmonary lobectomy, were entered into the study.
  • The prevalence of the occult tumor cells was not related to age, gender, tumor stage, histological differentiation or grade.
  • This result did not change when grouping the patients by tumor stage.
  • The stage was the best predictor of cancer recurrence (Cox proportional hazards model ratio: 2.09; p = 0.0026).
  • CONCLUSIONS: This study confirms that immunocytochemical analysis detects occult tumor cells in the bone marrow of at least 25% of patients surgically treated for stage I and II non-small-cell lung cancer.
  • [MeSH-major] Bone Marrow Neoplasms / metabolism. Bone Marrow Neoplasms / pathology. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / metabolism. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Bone Marrow / metabolism. Bone Marrow / pathology. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / secondary. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Humans. Immunohistochemistry. Keratin-18 / metabolism. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18594145.001).
  • [ISSN] 1421-9921
  • [Journal-full-title] European surgical research. Europäische chirurgische Forschung. Recherches chirurgicales européennes
  • [ISO-abbreviation] Eur Surg Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Keratin-18
  •  go-up   go-down


71. Cortas T, Eisenberg R, Fu P, Kern J, Patrick L, Dowlati A: Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer. Lung Cancer; 2007 Mar;55(3):349-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer.
  • METHODS: 145 patients underwent lung resection for NSCLC at University Hospitals from 1998-2002.
  • A database with TNM stage, gender, age, time to recurrence, and survival was established. p-EGFR and p-STAT-3 levels were quantified by IHC.
  • 58% were female and 54% had adenocarcinoma.
  • Pathologic stage was as follows: stage I: 54%, stage II: 31%, stage III: 15%.
  • 32% were positive for p-EGFR (squamous 36%, adenocarcinoma 29%).
  • p-STAT-3 staining was seen in 38% and was higher in adenocarcinoma (46%) versus squamous cell (27%, p=0.02) and was higher in patients >70 years than compared to those <70 years (p=0.06).
  • CONCLUSIONS: Although EGFR is commonly expressed in NSCLC ( approximately 70%), p-EGFR is seen in only 1/3 of patients. p-EGFR and p-STAT-3 were commonly co-expressed in tumors compatible with known signal transduction pathways in lung cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Receptor, Epidermal Growth Factor / metabolism. STAT3 Transcription Factor / metabolism


72. Lin DM, Ma Y, Zheng S, Liu XY, Zou SM, Wei WQ: Prognostic value of bronchioloalveolar carcinoma component in lung adenocarcinoma. Histol Histopathol; 2006 06;21(6):627-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of bronchioloalveolar carcinoma component in lung adenocarcinoma.
  • BAC is a common pattern in conventional lung adenocarcinoma.
  • As a result, it was difficult to evaluate the prognosis on this type of lung adenocarcinoma.
  • Though the 1999 WHO classification of BAC provides a useful framework, it does not provide detailed enough information to predict prognosis in lung adenocarcinomas with BAC feature.
  • The aim of this study was to address the prognostic value of bronchioloalveolar carcinoma (BAC) component in lung adenocarcinoma.
  • Ninety-one consecutive surgically treated patients with adenocarcinoma exhibiting various degrees of BAC features and complete follow-up records were retrospectively studied.
  • According to the percentage of BAC component designed as less than 50%, 50%-79%, 80%-99%, and 100%, tumors were classified as type I, type II, type III, and type IV respectively.
  • Multivariate analysis revealed that the four classified types are independent prognostic factors (P=0.0008), as is tumor stage (P=0.0000).
  • The 5-year survival rates were 39.29%, 58.82%, 81.25%, 85.71% for the four classified types respectively, and were 88.89% for stage I, 46.15% for stage II, and 23.81% for stage III.
  • In lung adenocarcinoma, the BAC component may prove to be useful to predict the outcome of the patients, and the percentage of BAC pattern and pathological stage appear to be two independent prognostic factors.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16528673.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


73. Health Quality Ontario: Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. Ont Health Technol Assess Ser; 2010;10(24):1-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
  • For each technology, an economic analysis was also completed by the Toronto Health Economics and Technology Assessment Collaborative (THETA) and is summarized within the reports.THE FOLLOWING REPORTS CAN BE PUBLICLY ACCESSED AT THE MAS WEBSITE AT: http://www.health.gov.on.ca/mas or at www.health.gov.on.ca/english/providers/program/mas/mas_about.htmlGENE EXPRESSION PROFILING FOR GUIDING ADJUVANT CHEMOTHERAPY DECISIONS IN WOMEN WITH EARLY BREAST CANCER: An Evidence-Based AnalysisEpidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: an Evidence-Based AnalysisK-RAS testing in Treatment Decisions for Advanced Colorectal Cancer: an Evidence-Based Analysis OBJECTIVE: The Medical Advisory Secretariat undertook a systematic review of the evidence on the clinical effectiveness and cost-effectiveness of epidermal growth factor receptor (EGFR) mutation testing compared with no EGFR mutation testing to predict response to tyrosine kinase inhibitors (TKIs), gefitinib (Iressa(®)) or erlotinib (Tarceva(®)) in patients with advanced non-small cell lung cancer (NSCLC).
  • CLINICAL NEED: TARGET POPULATION AND CONDITION With an estimated 7,800 new cases and 7,000 deaths last year, lung cancer is the leading cause of cancer deaths in Ontario.
  • Certain patient characteristics (adenocarcinoma, non-smoking history, Asian ethnicity, female gender) predict for better survival benefit and response to therapy with TKIs.
  • METHODS: A literature search was performed on March 9, 2010 using OVID MEDLINE, MEDLINE In-Process and Other Non-Indexed Citations, OVID EMBASE, Wiley Cochrane, CINAHL, Centre for Reviews and Dissemination/International Agency for Health Technology Assessment for studies published from January 1, 2004 until February 28, 2010 using the following terms: Non-Small-Cell Lung CarcinomaEpidermal Growth Factor ReceptorAn automatic literature update program also extracted all papers published from February 2010 until August 2010.
  • The inclusion criteria were as follows: POPULATION: patients with locally advanced or metastatic NSCLC (stage IIIB or IV)PROCEDURE: EGFR mutation testing before treatment with gefitinib or erlotinibLANGUAGE: publication in EnglishPublished health technology assessments, guidelines, and peer-reviewed literature (abstracts, full text, conference abstract) OUTCOMES: progression-free survival (PFS), Objective response rate (ORR), overall survival (OS), quality of life (QoL).The exclusion criteria were as follows: Studies lacking outcomes specific to those of interestStudies focused on erlotinib maintenance therapyStudies focused on gefitinib or erlotinib use in combination with cytotoxic agents or any other drugGrey literature, where relevant, was also reviewed.
  • OUTCOMES OF INTEREST: PFSORR determined by means of the Response Evaluation Criteria in Solid Tumours (RECIST)OSQoL QUALITY OF EVIDENCE: The quality of the Phase II trials and observational studies was based on the method of subject recruitment and sampling, possibility of selection bias, and generalizability to the source population.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1992 Sep 1;70(5):1102-10 [1515985.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1453-61 [1649267.001]
  • [Cites] J Clin Oncol. 1988 Apr;6(4):633-41 [2833577.001]
  • [Cites] Methods Enzymol. 1983;99:379-87 [6196602.001]
  • [Cites] Int J Technol Assess Health Care. 1994 Fall;10(4):714-5 [7843894.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):191-202 [8000996.001]
  • [Cites] Pharmacoeconomics. 1995 Oct;8(4):316-23 [10155673.001]
  • [Cites] Lung Cancer. 1999 Apr;24(1):17-24 [10403690.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Jun;31(6):637-43 [10404636.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):12-8 [10458212.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3522-30 [10550150.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 5:S3-6 [10582131.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):122-30 [10623702.001]
  • [Cites] Lung Cancer. 2000 Mar;27(3):145-57 [10699688.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] Br J Cancer. 2000 Aug;83(4):447-53 [10945489.001]
  • [Cites] Cancer. 2000 Oct 15;89(8):1714-9 [11042565.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1295-300 [11106119.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1344-52 [11870178.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1 Suppl 1):3-11 [12644979.001]
  • [Cites] Exp Cell Res. 2003 Mar 10;284(1):31-53 [12648464.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):337-43 [12872354.001]
  • [Cites] Lung Cancer. 2003 Sep;41(3):321-31 [12928123.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3207-13 [12947054.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1192-9 [14520444.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):38-44 [14679117.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1589-97 [15117980.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):208-12 [15187994.001]
  • [Cites] BMJ. 2004 Jun 19;328(7454):1490 [15205295.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3238-47 [15310767.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):1996-2004 [15558071.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):15-20 [15597104.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):90-6 [15598944.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(1):81-92 [15617993.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):294-9 [15668287.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):857-65 [15681531.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):538-48 [15746148.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6838-45 [15998906.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6829-37 [15998907.001]
  • [Cites] Chest. 2005 Jul;128(1):452-62 [16002972.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5007-18 [16051952.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8081-92 [16204011.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8389-95 [16293869.001]
  • [Cites] Jpn J Clin Oncol. 2005 Dec;35(12):700-6 [16303792.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):467-72 [16371411.001]
  • [Cites] Lung Cancer. 2006 Apr;52(1):75-81 [16488054.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1428-34 [16549837.001]
  • [Cites] Anticancer Drugs. 2006 Apr;17(4):401-9 [16549997.001]
  • [Cites] Lung Cancer. 2006 May;52(2):155-63 [16569462.001]
  • [Cites] Chest. 2006 Apr;129(4):1031-8 [16608954.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3078-84 [16707605.001]
  • [Cites] Int J Clin Oncol. 2006 Jun;11(3):190-8 [16850125.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4539-44 [17008692.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):317-23 [17079694.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7232-41 [17189394.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1239-47 [17192902.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):752-60 [17317677.001]
  • [Cites] Cancer. 2007 May 1;109(9):1836-44 [17387741.001]
  • [Cites] J Thorac Oncol. 2006 Oct;1(8):837-46 [17409968.001]
  • [Cites] Lung Cancer. 2007 Aug;57(2):168-74 [17467848.001]
  • [Cites] Lung Cancer. 2007 Oct;58(1):80-7 [17588704.001]
  • [Cites] Health Qual Life Outcomes. 2008;6:6 [18208616.001]
  • [Cites] Cancer. 2008 Mar 1;112(5):1114-21 [18219661.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):983-94 [18281673.001]
  • [Cites] Ann Oncol. 2008 May;19(5):939-45 [18283036.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1160-74 [18337605.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1452-8 [18349395.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1472-8 [18349398.001]
  • [Cites] Lung Cancer. 2008 Dec;62(3):334-43 [18450322.001]
  • [Cites] Br J Cancer. 2008 May 20;98(10):1608-13 [18475293.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3543-51 [18506025.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3860-6 [18559606.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3867-74 [18559607.001]
  • [Cites] Clin Lung Cancer. 2008 May;9(3):154-9 [18621625.001]
  • [Cites] J Clin Oncol. 2008 Sep 10;26(26):4268-75 [18626007.001]
  • [Cites] Int J Med Sci. 2008;5(4):209-17 [18645621.001]
  • [Cites] Chin Med J (Engl). 2008 May 20;121(10):892-7 [18706202.001]
  • [Cites] Lancet. 2008 Nov 22;372(9652):1809-18 [19027483.001]
  • [Cites] J Thorac Oncol. 2008 Dec;3(12):1446-53 [19057271.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Jul;64(2):379-84 [19139896.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1227-34 [19188680.001]
  • [Cites] Chang Gung Med J. 2008 Nov-Dec;31(6):559-66 [19241895.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2253-60 [19289623.001]
  • [Cites] Eur Respir J. 2009 Jun;33(6):1485-97 [19483050.001]
  • [Cites] J Thorac Oncol. 2009 Sep;4(9):1148-55 [19546818.001]
  • [Cites] J Thorac Oncol. 2009 Aug;4(8):1002-9 [19633475.001]
  • [Cites] Oncogene. 2009 Aug;28 Suppl 1:S14-23 [19680292.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):947-57 [19692680.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):958-67 [19692684.001]
  • [Cites] Ann Oncol. 2010 Mar;21(3):556-61 [19828561.001]
  • [Cites] Lancet Oncol. 2010 Feb;11(2):121-8 [20022809.001]
  • [Cites] Clin Cancer Res. 2010 Jan 1;16(1):291-303 [20028749.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):744-52 [20038723.001]
  • [Cites] Clin Cancer Res. 2010 Feb 15;16(4):1307-14 [20145166.001]
  • [Cites] J Natl Cancer Inst. 2010 Mar 3;102(5):298-306 [20160168.001]
  • [Cites] J Clin Oncol. 2010 May 1;28(13):2167-73 [20351334.001]
  • [Cites] Curr Drug Targets. 2010 Jul;11(7):851-64 [20388064.001]
  • [Cites] N Engl J Med. 2010 Jun 24;362(25):2380-8 [20573926.001]
  • [Cites] Lung Cancer. 2003 Aug;41 Suppl 1:S9-14 [12867057.001]
  • (PMID = 23074402.001).
  • [ISSN] 1915-7398
  • [Journal-full-title] Ontario health technology assessment series
  • [ISO-abbreviation] Ont Health Technol Assess Ser
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3377519
  •  go-up   go-down


74. Kim YS, Yoon SM, Choi EK, Yi BY, Kim JH, Ahn SD, Lee SW, Shin SS, Lee JS, Suh C, Kim SW, Kim DS, Kim WS, Park HJ, Park CI: Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non-small-cell lung cancer. Int J Radiat Oncol Biol Phys; 2005 May 1;62(1):76-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non-small-cell lung cancer.
  • PURPOSE: To evaluate the efficacy and toxicity of concurrent chemoradiotherapy with paclitaxel/cisplatin for Stage IIIB locally advanced non-small-cell lung cancer (NSCLC).
  • The 2-year overall and progression-free survival rates were 37% and 18%, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Dose Fractionation. Female. Humans. Male. Middle Aged. Multivariate Analysis. Paclitaxel / administration & dosage. Prospective Studies. Survival Analysis. Treatment Outcome


75. Han PH, Li XJ, Qin H, Yao J, DU N, Ren H: [Upregulation of survivin in non-small cell lung cancer and its clinicopathological correlation with p53 and Bcl-2]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Aug;25(8):710-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Upregulation of survivin in non-small cell lung cancer and its clinicopathological correlation with p53 and Bcl-2].
  • AIM: To retrospectively analyze the clinicopathological data of 87 non-small cell lung cancer (NSCLC) specimens and explore the clinicopathological correlation of survivin with p53 and Bcl-2 and the applicability of combined detection for NSCLC prognosis.
  • NSCLC at various stages showed significant difference in the positivity of survivin: at stage III and IV (mid and late stage) was 71.1% (32/45) while at stage I and II (early and mid stage) was 38.1% (16/42, P<0.01).
  • Survivin was detected in 76.0% (38/50) squamous cell carcinoma and 27.0% (10/37) of adenocarcinoma in a significantly different manner (P<0.01).
  • Moreover, p53 expression was tissue-specific whereby the positivity with squamous cell carcinoma (76.0%, 38/50) was significantly higher than that with adenocarcinoma (27.0%), (10/37, P<0.01).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / pathology. Gene Expression Regulation, Neoplastic. Microtubule-Associated Proteins / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism. Up-Regulation

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664395.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


76. Wang J, Kuo YF, Freeman J, Markowitz AB, Goodwin JS: Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer. Cancer; 2008 Jan 15;112(2):382-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer.
  • BACKGROUND: The authors assessed patterns of perioperative chemotherapy use in elderly patients with resected stage I, II, or IIIA nonsmall cell lung cancer (NSCLC) from 1992 to 2002.
  • METHODS: By using data from the Surveillance, Epidemiology, and End Results Program, 11,807 patients were identified who had resected stage I, II, or IIIA NSCLC between 1992 and 2002 and survived >or=120 days beyond diagnosis.
  • RESULTS: In total, 957 patients with stage I, II, or IIIA NSCLC (8.1% of the study population) received perioperative chemotherapy.
  • The proportion of patients receiving chemotherapy for stage I NSCLC changed little during the study period.
  • Of 3230 patients with stage II and IIIA NSCLC, 609 patients (18.9%) received chemotherapy, 423 patients (13%) received chemotherapy combined with radiation.
  • Younger age, being married, having advanced-stage tumor or adenocarcinoma, having a later diagnosis year, receiving radiation, and seeing an oncologist were predictors for the receipt of chemotherapy (P< .001).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy


77. Sugane T, Baba M, Imai R, Nakajima M, Yamamoto N, Miyamoto T, Ezawa H, Yoshikawa K, Kandatsu S, Kamada T, Mizoe J, Tsujii H: Carbon ion radiotherapy for elderly patients 80 years and older with stage I non-small cell lung cancer. Lung Cancer; 2009 Apr;64(1):45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbon ion radiotherapy for elderly patients 80 years and older with stage I non-small cell lung cancer.
  • Surgical resection is the standard treatment for stage I non-small cell lung cancer (NSCLC).
  • Different modalities to treat stage I NSCLC have been developed, such as stereotactic radiotherapy (SRT), proton beam radiotherapy and carbon ion radiotherapy (CIRT).
  • Between April 1999 and November 2003, we treated 129 patients with stage I NSCLC using CIRT.
  • In this study, we focused on 28 patients aged 80 years and older who underwent CIRT, and analyzed the effectiveness of CIRT in treating their lung cancer and the impact on their activity of daily life (ADL).
  • Our data demonstrate that CIRT was effective in treating elderly patients with stage I NSCLC.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carbon Radioisotopes / therapeutic use. Carcinoma, Squamous Cell / radiotherapy. Lung Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18762351.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Carbon Radioisotopes
  •  go-up   go-down


78. Wozniak AJ, Belzer K, Heilbrun LK, Kucuk O, Gadgeel S, Kalemkerian GP, Venkatramanamoorthy R, Kraut MJ: Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung cancer. Clin Lung Cancer; 2007 Mar;8(5):313-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung cancer.
  • PURPOSE: This phase II study evaluated the efficacy and toxicity of gemcitabine/paclitaxel given every 2 weeks in patients with advanced-stage non-small-cell lung cancer.
  • The median age was 61 years, and the majority of patients had adenocarcinoma and stage IV disease.
  • CONCLUSION: Gemcitabine/paclitaxel is active in the treatment of non-small-cell lung cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17562230.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Grant] United States / PHS HHS / / CAA-22453
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


79. Little AG, Gay EG, Gaspar LE, Stewart AK: National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer; 2007 Sep;57(3):253-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care.
  • PURPOSE: To determine the epidemiology, pathology and patterns of care for patients with non-small cell lung cancer (NSCLC) in the United States.
  • Slightly more than half were older than 70 years; 58.5% were male and 35% had adenocarcinoma.
  • 67.2% of patients had Stage III or IV disease.
  • More of the Hispanic, Asian or Black patients than White had Stage IV disease (p<0.01).
  • Surgery alone was primarily utilized for patients in Stage I or II.
  • Choice of treatment correlated more with stage and age than comorbidities.
  • CONCLUSION: Our results substantiated the pattern of increasing proportions of women with NSCLC and the increasing frequency of adenocarcinoma.
  • Most patients presented with Stage III or IV disease.
  • Ethnic minorities were more likely to present in late stage disease than Whites.
  • Treatment strategies depended more on stage and age than comorbid burden.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / epidemiology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / epidemiology. Lung Neoplasms / pathology


80. Hata M, Tokuuye K, Kagei K, Sugahara S, Nakayama H, Fukumitsu N, Hashimoto T, Mizumoto M, Ohara K, Akine Y: Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. Int J Radiat Oncol Biol Phys; 2007 Jul 1;68(3):786-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study.
  • PURPOSE: To present treatment outcomes of hypofractionated high-dose proton beam therapy for Stage I non-small-cell lung cancer (NSCLC).
  • METHODS AND MATERIALS: Twenty-one patients with Stage I NSCLC (11 with Stage IA and 10 with Stage IB) underwent hypofractionated high-dose proton beam therapy.
  • Histology was squamous cell carcinoma in 6 patients, adenocarcinoma in 14, and large cell carcinoma in 1.
  • The 2-year overall and cause-specific survival rates were 74% and 86%, respectively.
  • Five patients showed recurrences 6-29 months after treatment, including local progression and new lung lesions outside of the irradiated volume in 1 and 4 patients, respectively.
  • CONCLUSIONS: Hypofractionated high-dose proton beam therapy seems feasible and effective for Stage I NSCLC.
  • Proton beams may contribute to enhanced efficacy and lower toxicity in the treatment of patients with Stage I NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Dose Fractionation. Lung Neoplasms / radiotherapy. Neoplasm Recurrence, Local / prevention & control. Protons / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17379439.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


81. Levchenko EV, Moiseyenko VM, Matsko DE, Iyevleva AG, Ivantsov AO, Yargnian SM, Anisimov VV, Semionov II, Imyanitov EN: Down-staging of EGFR mutation-positive advanced lung carcinoma with gefitinib followed by surgical intervention: follow-up of two cases. Onkologie; 2009 Nov;32(11):674-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-staging of EGFR mutation-positive advanced lung carcinoma with gefitinib followed by surgical intervention: follow-up of two cases.
  • BACKGROUND: Non-small cell lung carcinomas (NSCLC) carrying a mutation in the epidermal growth factor receptor (EGFR) gene show unprecedented sensitivity to gefitinib or erlotinib.
  • CASE REPORTS: We present the follow-up data of 2 EGFR mutation-positive stage IV NSCLC patients who received upfront 250 mg gefitinib daily, then underwent potentially curative surgery, and resumed gefitinib therapy in the adjuvant setting.
  • Patient 1 was diagnosed with a rightsided adenocarcinoma of the upper lobe with multiple metastases to the middle lobe.
  • Patient 2 presented with adenocarcinoma of the lower lobe of the right lung and a single metastasis to the left adrenal.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery. Protein Kinase Inhibitors / administration & dosage. Quinazolines / administration & dosage. Receptor, Epidermal Growth Factor / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Onkologie. 2009 Nov;32(11):627-8 [19887865.001]
  • (PMID = 19887873.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


82. Peng Z, Shan C, Wang H: [Expression of VHL and HIF-1alpha and its clinical significance in the lung cancer tissue]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Apr;34(4):331-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of VHL and HIF-1alpha and its clinical significance in the lung cancer tissue].
  • OBJECTIVE: To investigate the expression of von Hippel-Lindau (VHL) protein and hypoxia inducible factor-1alpha (HIF-1alpha) in the lung cancer tissue and to detect their clinical significance.
  • METHODS: EnVisionTM immunohistochemistry was used for detecting the expression of VHL and HIF-1alpha in routinely paraffin-embedded sections from the specimens of lung cancer (n=80) and normal lung tissues (n=20).
  • We also analyzed the relation between the expression of VHL and HIF-1alpha and the clinical stage,differentiation,and with or without lymphatic metastasis.
  • RESULTS: The positive rate of VHL was significantly lower in lung cancer (56.3%) than that in normal lung tissues (90.0%)(P<0.01).The positive rate of HIF-1alpha was significantly higher in lung cancer (65.0%) than that in normal lung tissues (20.0%)(P<0.01).
  • The positive rate of VHL was significantly higher in the middle and high-differentiated, StageI~II, and no-metastasis of lymph node lung cancer tissues than that in the poorly-differentiated, Stage III~IV, metastasis of lymph node lung cancer tissues (P<0.01~0.05) .But the expression of HIF-1alpha in the lung cancer tissues was just the opposite as compared with that of VHL (P<0.05) .VHL and HIF-1alpha expression levels showed highly negative correlation (P<0.01).
  • CONCLUSION: The expression of VHL and HIF-1alpha may be important biological markers for carcinogenesis, progression, clinical biological behaviors, and prognosis of lung cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Lung Neoplasms / metabolism. Von Hippel-Lindau Tumor Suppressor Protein / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19411751.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


83. Aguiló R, Macià F, Porta M, Casamitjana M, Minguella J, Novoa AM: Multiple independent primary cancers do not adversely affect survival of the lung cancer patient. Eur J Cardiothorac Surg; 2008 Nov;34(5):1075-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple independent primary cancers do not adversely affect survival of the lung cancer patient.
  • Objectives of this study were to analyze clinical characteristics, organ location, and prognosis associated with the presentation of multiple independent primaries when a lung cancer is involved.
  • METHODS: We analyzed all patients with a histology-proven diagnosis of lung cancer registered from January 1990 to December 2004 at the Tumor Registry of the Hospital del Mar, Barcelona.
  • We compared 1686 patients presenting a lung cancer as unique primary versus 228 patients presenting a lung cancer and another independent primary.
  • Cofactors included age, sex, smoking habit, lung cancer histology and stage, type and intention of treatment, organ location of the other cancer, and survival from the date of lung cancer diagnosis.
  • Independent risk factors of cancer multiplicity were smoking (OR: 3.99; 95% CI: 1.4-11.2), lung cancer stages I (OR: 1.84; 95% CI: 1.2-2.9) and II (OR: 3.25; 95% CI: 1.7-6.3), and older age (OR: 3.11; 95% CI: 1.9-5.1).
  • Once adjusted by age and sex, the main determinant of survival was lung cancer stage rather than cancer multiplicity.
  • However, patients with multiple cancers presented a slightly better survival than patients with a lung cancer as unique primary.
  • When analyzed by subgroups, survival was higher in patients with the lung cancer first (HR: 0.44; 95% CI: 0.24-0.80), and in patients with the other cancer first (HR: 0.80; 95% CI: 0.65-0.99), but it was not different in the patients with a lung cancer and a synchronous other cancer (HR: 0.80; 95% CI: 0.52-1.15).
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Small Cell Lung Carcinoma / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824369.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


84. Garrido P, González-Larriba JL, Insa A, Provencio M, Torres A, Isla D, Sanchez JM, Cardenal F, Domine M, Barcelo JR, Tarrazona V, Varela A, Aguilo R, Astudillo J, Muguruza I, Artal A, Hernando-Trancho F, Massuti B, Sanchez-Ronco M, Rosell R: Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol; 2007 Oct 20;25(30):4736-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.
  • PURPOSE: To assess the activity of induction chemotherapy followed by surgery in stage IIIA and selected stage IIIB non-small-cell lung cancer patients.
  • The overall complete resection rate was 68.9% of patients eligible for surgery (72% of stage IIIA patients and 66% of stage IIIB patients) and 48% of all assessable patients.
  • The median overall survival time was 15.9 months, 3-year survival rate was 36.8%, and 5-year survival rate was 21.1%, with no significant differences in survival between stage IIIA and stage IIIB patients.
  • CONCLUSION: Induction chemotherapy followed by surgery is effective in stage IIIA and in selected stage IIIB patients attaining complete resection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction. Survival Rate. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17947721.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


85. Wislez M, Antoine M, Baudrin L, Poulot V, Neuville A, Pradere M, Longchampt E, Isaac-Sibille S, Lebitasy MP, Cadranel J: Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer; 2010 May;68(2):185-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.
  • There is no optimal established therapy for treating advanced or recurrent adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC), and it remains unclear whether chemotherapy achieves therapeutic results comparable to those seen in the more common non-small lung carcinoma subtypes.
  • Fifty pathological samples were obtained from 62 patients included in a multicenter prospective phase II trial (IFCT0401) conducted to evaluate gefitinib as a first-line therapy for non-resectable ADC-BAC.
  • We demonstrated that demographic data, clinical characteristics and stage at presentation (extrathoracic versus lung metastasis, as well as TNM staging) did not distinguish between the two subtypes.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Mucinous / diagnosis. DNA-Binding Proteins / metabolism. Lung Neoplasms / diagnosis. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19581016.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Quinazolines; 0 / TTF1 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


86. Hanagiri T, Oka S, Takenaka S, Baba T, Yasuda M, Ono K, So T, Uramoto H, Takenoyama M, Yasumoto K: Results of surgical resection for patients with large cell carcinoma of the lung. Int J Surg; 2010;8(5):391-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of surgical resection for patients with large cell carcinoma of the lung.
  • PURPOSE: The clinical features of large cell carcinoma (LCC) of the lung have remained unclear due to the low incidence of the disease.
  • The mean smoking pack-year index was 49.9 in the patients with LCC, 27.1 in 625 patients with adenocarcinoma, and 52.5 in 266 patients with squamous cell carcinoma, and this was significantly higher in the patients with LCC than in those with adenocarcinoma.
  • The mean tumor diameter was 38 mm for LCC, 28 mm for adenocarcinoma, and 39 mm for squamous cell carcinoma.
  • The pathological stage was IA in 11 patients, IB in 11, II in 12, IIIA in 16, IIIB in 5, and IV in 2.
  • The post-operative 5-year survival rate was 60.5% for LCC, 64.3% for large cell neuroendocrine carcinoma, 67.0% for adenocarcinoma, and 50.1% for squamous cell carcinoma.
  • CONCLUSION: The tumor diameter was significantly larger for LCC than for adenocarcinoma at the time of diagnosis.
  • The proportion of smokers and the smoking pack-year index in patients with LCC were significantly higher than those of adenocarcinoma.
  • The surgical results were similar between LCC and other non-small cell lung carcinomas.
  • [MeSH-major] Carcinoma, Large Cell / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20547250.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


87. Ho C, Ross H, Davies A: Phase II trial of premetrexed in patients with selected stage IIIB/IV bronchioloalveolar carcinoma. Clin Lung Cancer; 2006 Nov;8(3):220-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of premetrexed in patients with selected stage IIIB/IV bronchioloalveolar carcinoma.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Antineoplastic Agents / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17239300.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


88. Masuda N, Matsui K, Negoro S, Takeda K, Kudoh S, Nakagawa K, Mukaiyama A, Arase H, Yoshida P, Ijima T, Takada M, Fukuoka M: Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer. Clin Lung Cancer; 2010 Jul 1;11(4):271-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer.
  • PURPOSE: We conducted a phase I trial of the topoisomerase I inhibitor topotecan for the purpose of determining the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of topotecan when administered weekly to patients with advanced non-small-cell lung cancer.
  • PATIENTS AND METHODS: Twelve patients with stage IIIB or IV disease were treated with topotecan by 30-minute intravenous infusion on days 1, 8, and 15 every 4 weeks.
  • CONCLUSION: The recommended dose of topotecan for phase II studies in previously untreated patients is 6 mg/m2 on days 1, 8, and 15, every 28 days, and 4 mg/m2 appears to be a suitable dose for use in previously treated patients with this schedule.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Salvage Therapy. Topotecan / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Drug Resistance, Neoplasm. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Survival Rate. Tissue Distribution. Treatment Outcome


89. Duan Y, Yu LJ, Lu PO, Wang WZ: [Correlation between SUV of (18)F-FDG PET-CT and the expression of GLUT1, MVD and Ki67 in non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi; 2008 Oct;30(10):764-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between SUV of (18)F-FDG PET-CT and the expression of GLUT1, MVD and Ki67 in non-small cell lung cancer].
  • OBJECTIVE: To investigate the correlation between 18F-FDG standard uptake value (SUV) and expression of GLUT1, MVD and Ki67 in non-small cell lung cancer (NSCLC).
  • METHODS: Thirty-three patients with non-small cell lung cancer received preoperative 18F-FDG PET-CT examination and underwent surgery.
  • RESULTS: Of the 33 NSCLC patients, 21 were in stage I, 4 in stage II and 8 in stage IIIa.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Fluorodeoxyglucose F18 / pharmacokinetics. Glucose Transporter Type 1 / metabolism. Ki-67 Antigen / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / radionuclide imaging. Adult. Aged. Antigens, CD34 / metabolism. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Humans. Lymphatic Metastasis. Male. Microvessels / radionuclide imaging. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Radiopharmaceuticals / pharmacokinetics. Tomography, X-Ray Computed. Tumor Burden

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173807.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Glucose Transporter Type 1; 0 / Ki-67 Antigen; 0 / Radiopharmaceuticals; 0 / SLC2A1 protein, human; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


90. Belderbos JS, Heemsbergen WD, De Jaeger K, Baas P, Lebesque JV: Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys; 2006 Sep 1;66(1):126-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy.
  • PURPOSE: The aim of this study was to determine the maximum tolerated dose (MTD) delivered within 6 weeks in patients with non-small-cell lung cancer (NSCLC).
  • METHODS AND MATERIALS: A Phase I/II trial was performed including inoperable NSCLC patients.
  • According to the relative mean lung dose (rMLD), five risk groups with different starting doses were defined: Group 1, rMLD 0.0 to 0.12; Group 2, rMLD 0.12 to 0.18; Group 3, rMLD 0.18 to 0.24; Group 4, rMLD 0.24 to 0.31; and Group 5, rMLD 0.31 to 0.40.
  • Tumor Stage I or II was found in 53%, IIIA in 31%, and IIIB in 17%.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Lung Neoplasms / radiotherapy. Radiotherapy, Conformal / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16904518.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


91. Xiong JP, Feng M, Qiu F, Xu J, Tao QS, Zhang L, Xiang XJ, Zhong LX, Yu F, Ma XT, Gong WY: Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Lung Cancer; 2008 May;60(2):208-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer.
  • PURPOSE: To evaluate the efficacy and safety of the combination of gemcitabine at a low dose of 250 mg/m(2) in 6h prolonged infusion with cisplatin in chemonaive patients with advanced non-small cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: Fifty-eight chemonaive patients with stage IIIB or IV NSCLC were included, 39 males and 19 females, with a median age 61 years (range 28-73).
  • Thirty-four (58.6%) patients had adenocarcinoma, 18 (31.0%) squamous cell, and 6 (10.4%) others.
  • Seventeen (29.3%) had stage IIIB and 41 (70.7%) stage IV.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / antagonists & inhibitors. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy


92. Koyama N, Jinn Y, Takabe K, Yoshizawa M, Usui Y, Inase N, Miyake S, Yoshizawa Y, Hagiwara K, Kanazawa M: The characterization of gefitinib sensitivity and adverse events in patients with non-small cell lung cancer. Anticancer Res; 2006 Nov-Dec;26(6B):4519-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The characterization of gefitinib sensitivity and adverse events in patients with non-small cell lung cancer.
  • BACKGROUND: Factors predicting gefitinib sensitivity and adverse events in non-small cell lung cancer (NSCLC) remain controversial.
  • RESULTS: Female, non-smoker, adenocarcinoma of stage I-II, and gefitinib effectiveness correlated with longer time to progression (TTP) and overall survival (OS), while the rate of interstitial lung disease in patients undergoing thoracic radiotherapy and stomatitis in females or those who never smoked were significantly higher.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use


93. Inamura K, Togashi Y, Okui M, Ninomiya H, Hiramatsu M, Satoh Y, Okumura S, Nakagawa K, Shimoji T, Noda T, Ishikawa Y: HOXB2 as a novel prognostic indicator for stage I lung adenocarcinomas. J Thorac Oncol; 2007 Sep;2(9):802-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HOXB2 as a novel prognostic indicator for stage I lung adenocarcinomas.
  • BACKGROUND: Outcomes of patients with lung adenocarcinomas can be predicted to some extent from the pathologic stage (p-stage).
  • Although all attempts are made to fully remove cancer lesions, still a number of p-stage I patients without metastatic disease at the time of surgery develop recurrences and die of cancer.
  • It is thus very important to identify p-stage I patients who are at risk of recurrence.
  • Using real-time reverse-transcriptase polymerase chain reaction analysis, we investigated the transcriptional levels of the top metastasis-related genes using 96 independent test lung adenocarcinoma samples and investigated their correlations with the prognosis.
  • RESULTS AND CONCLUSIONS: We document evidence that p-stage I patients with HOXB2 up-regulation have a worse prognosis than those with HOXB2 down-regulation (p = 0.0065), whereas the HOXB2 status has no prognostic significance for p-stage II-IV patients.
  • Comparing tumors and corresponding normal lung tissue, we confirmed HOXB2 up-regulated lesions to have much higher HOXB2 expression than the corresponding normal tissue.
  • [MeSH-major] Adenocarcinoma. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Lung Neoplasms. RNA, Neoplasm / genetics. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Thorac Oncol. 2008 Jan;3(1):100. Ishikawa, Yuichi [added]
  • (PMID = 17805056.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HOXB2 protein, human; 0 / Homeodomain Proteins; 0 / Nuclear Proteins; 0 / RNA, Neoplasm; 0 / Transcription Factors
  •  go-up   go-down


94. Yim J, Zhu LC, Chiriboga L, Watson HN, Goldberg JD, Moreira AL: Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol; 2007 Feb;20(2):233-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic features are important prognostic indicators in early stages lung adenocarcinomas.
  • Surgical specimens from 141 patients with clinical stage I or II lung adenocarcinoma during the period 1992-2004 were included.
  • These cases were classified into four groups defined by the extent of the bronchioloalveolar carcinoma component: group I: pure bronchioloalveolar carcinoma; group II: mixed subtype with predominant bronchioloalveolar carcinoma component and < or = 5 mm invasive component; group III: mixed subtype with bronchioloalveolar carcinoma component and > 5 mm invasive component; group IV: invasive carcinoma with no bronchioloalveolar carcinoma component.
  • The reported proportion of deaths ranged from 0% for groups I and II, 20% in patients with predominant invasive component with bronchioloalveolar carcinoma (group III), and 18% in patients with invasive carcinomas and no bronchioloalveolar carcinoma component (group IV).
  • The difference between the proportion of patients with reported deaths in the time period of this study in the combined greater than 5 mm+pure invasive groups (groups III, IV), and the < 5 mm + noninvasive groups (groups I, II) is statistically significant.
  • These results suggest that histological features may be useful in defining categories of lung adenocarcinomas with differing survival and prognostic features.
  • These results are helpful in defining a subcategory of 'minimally invasive adenocarcinoma', which has features similar to bronchioloalveolar carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17192789.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


95. Sirbu H, Schreiner W, Dalichau H, Busch T: Surgery for non-small cell carcinoma in geriatric patients: 15-year experience. Asian Cardiovasc Thorac Ann; 2005 Dec;13(4):330-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to determine the clinical patterns, short- and long-term survival in elderly patients after surgery for non-small cell lung carcinoma.
  • Advanced disease stage, low forced expiratory volume in 1 second, and previous cardiac disease were independent predictors that adversely influenced survival.
  • Geriatric patients with non-small cell lung carcinoma can undergo resection safely with acceptable long-term survival.
  • Careful attention to preoperative clinical staging is important as the elderly beyond the early stage of disease fare poorly.
  • Surgery is justified for the treatment of stage I-II lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy
  • [MeSH-minor] Adenocarcinoma / surgery. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Forced Expiratory Volume. Germany / epidemiology. Humans. Incidence. Male. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Sex Factors. Survival Analysis. Time. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304220.001).
  • [ISSN] 0218-4923
  • [Journal-full-title] Asian cardiovascular & thoracic annals
  • [ISO-abbreviation] Asian Cardiovasc Thorac Ann
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


96. Ready N, Jänne PA, Bogart J, Dipetrillo T, Garst J, Graziano S, Gu L, Wang X, Green MR, Vokes EE, Cancer, Leukemia Group B, Chicago, IL: Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol; 2010 Sep;5(9):1382-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
  • INTRODUCTION: This study evaluated the addition of gefitinib to sequential or concurrent chemoradiotherapy (CRT) in unresectable stage III non-small cell lung cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy. Mutation / genetics. Proto-Oncogene Proteins / genetics. Radiotherapy. Receptor, Epidermal Growth Factor / genetics. ras Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Aged. Carboplatin / administration & dosage. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / therapy. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Quinazolines / administration & dosage. Survival Rate. Treatment Outcome


97. Rego RL, Foster NR, Smyrk TC, Le M, O'Connell MJ, Sargent DJ, Windschitl H, Sinicrope FA: Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer; 2010 Jan 5;102(1):165-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Phospho-EGFR (Tyr-1173) and EGFR expression were analysed by immunohistochemistry (IHC) in tissue microarrays of TNM stage II and III colon cancers from completed adjuvant therapy trials (n=388).
  • Although phospho-EGFR was unrelated to clinicopathological variables, strong EGFR intensity was associated with higher tumour stage (P=0.03).
  • Stage and lymph node number were prognostic for DFS and OS, and histological grade for OS.
  • EGFR was an independent predictor of DFS (P=0.042) after adjustment for stage, histological grade, age, and MMR status.

  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7875-86 [14560030.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6487-501 [15475436.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]
  • [Cites] J Biol Chem. 1994 Jul 15;269(28):18674-8 [8034616.001]
  • [Cites] Eur J Surg Oncol. 1995 Jun;21(3):269-75 [7781795.001]
  • [Cites] Biochemistry. 1995 Dec 19;34(50):16456-66 [8845374.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):669-74 [8608874.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1713-8 [9563488.001]
  • [Cites] Clin Cancer Res. 1995 Jan;1(1):19-31 [9815883.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303 [10433618.001]
  • [Cites] J Biol Chem. 1999 Sep 10;274(37):26091-7 [10473558.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):102-8 [15598946.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1803-10 [15677699.001]
  • [Cites] Int J Oncol. 2005 Aug;27(2):317-25 [16010411.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1350-6 [15832190.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S59-62 [16399434.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1169-77 [16505437.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2834-43 [16510606.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2738-44 [16675565.001]
  • [Cites] Clin Colorectal Cancer. 2006 Jul;6(2):133-9 [16945169.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):729-37 [16952542.001]
  • [Cites] Br J Cancer. 2006 Dec 4;95(11):1525-8 [17088913.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1232-8 [17187355.001]
  • [Cites] Lung Cancer. 2007 Mar;55(3):349-55 [17161498.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2184-90 [17538163.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3597-604 [17575224.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4405-13 [17906204.001]
  • [Cites] Ann Oncol. 2008 Dec;19(12):2033-8 [18632722.001]
  • [Cites] Pathology. 2009;41(4):356-60 [19404848.001]
  • [Cites] Curr Opin Oncol. 2009 Jul;21(4):369-73 [19444104.001]
  • [Cites] Clin Cancer Res. 2009 Jul 15;15(14):4531-7 [19584170.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2225-31 [10786688.001]
  • [Cites] Int J Cancer. 2000 Oct 1;88(1):77-81 [10964085.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1521-6 [11818567.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1735-43 [11919229.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] Eur J Cancer. 2002 May;38(8):1065-71 [12008194.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(17):2258-64 [12441262.001]
  • [Cites] Eur J Cancer. 2003 Jul;39(10):1348-54 [12826036.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Virchows Arch. 2003 Aug;443(2):115-21 [12802583.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3069-75 [15131045.001]
  • (PMID = 19997103.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK084567; United States / NCI NIH HHS / CA / R01 CA104683; United States / NCI NIH HHS / CA / CA 104683
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 21820-51-9 / Phosphotyrosine; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2813748
  •  go-up   go-down


98. Herpel E, Muley T, Schneider T, Palm E, Kieslich de Hol D, Warth A, Meister M, Storz K, Schnabel PA, Schirmacher P, Dienemann H, Hoffmann H: A pragmatic approach to the diagnosis of nodal micrometastases in early stage non-small cell lung cancer. J Thorac Oncol; 2010 Aug;5(8):1206-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pragmatic approach to the diagnosis of nodal micrometastases in early stage non-small cell lung cancer.
  • INTRODUCTION: This study was designed to develop a both sensitive and efficient algorithm for detection of lymph node micrometastases and to determine its prognostic impact in patients with early stage non-small cell lung cancer (NSCLC).
  • METHODS: One hundred seventy patients with NSCLC p stage I and II were included in this study, of which n = 5299 lymph nodes were obtained and submitted to histopathologic analysis.
  • Survival differences between patients who were upstaged into stage II (N0>N1) and those remaining in stage I were not statistically significant (p = 0.537).
  • CONCLUSION: Extended workup of N2-lymph nodes using one broad-spectrum keratin marker in otherwise N2-negative lymph nodes may represent a both efficient and sensitive approach to the identification of micrometastases in dissected lymph nodes of patients with early stage NSCLC.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Lymph Nodes / pathology. Neoplasms, Squamous Cell / secondary

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20581709.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


99. Osako T, Shiraishi I, Oorui H: [Video-assisted thoracic surgery for lung cancer at Kyoto City Hospital]. Kyobu Geka; 2009 Apr;62(4):271-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Video-assisted thoracic surgery for lung cancer at Kyoto City Hospital].
  • From April 1994 to April 2008, we were started on 313 cases video-assisted thoracic surgery (VATS) operations for primary lung cancer at the thoracic surgical department of Kyoto City Hospital.
  • Histopathologic diagnosis was adenocarcinoma was 74% and squamous cell carcinoma was 22%.
  • Five year survival rate were stage IA 87.8%, IB 71.8%, II 52.4%, III 47.8%, IV 33.3%.
  • Our data demonstrate thoracoscopic lobectomy for lung cancer is a safe procedure and excellent prognosis.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods. Thoracic Surgery, Video-Assisted / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19348209.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


100. Yi D, Wiedmann TS: Inhalation adjuvant therapy for lung cancer. J Aerosol Med Pulm Drug Deliv; 2010 Aug;23(4):181-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhalation adjuvant therapy for lung cancer.
  • BACKGROUND: Lung cancer is the leading cause of new cancer cases and also is the number one cause of cancer death in both male and females in the United States and the world.
  • Lung cancer is histologically separated into either small-cell (SCLC) or nonsmall-cell lung cancer (NSCLC).
  • METHODS: The literature pertaining to lung cancer adjuvant therapy and inhalation lung cancer chemoprevention was reviewed.
  • RESULTS: It is argued that inhalation of chemotherapy as an adjuvant in Stage II NSCC and inhalation of chemopreventive agents in Stage I adenocarcinomas are direct paths to improve lung cancer therapy as well as demonstrate the utility of inhalation therapy.
  • CONCLUSIONS: If successful, inhalation delivery may be extended to the treatment of other types of lung cancer.
  • [MeSH-major] Adenocarcinoma / prevention & control. Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy. Respiratory Therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20073558.001).
  • [ISSN] 1941-2703
  • [Journal-full-title] Journal of aerosol medicine and pulmonary drug delivery
  • [ISO-abbreviation] J Aerosol Med Pulm Drug Deliv
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down






Advertisement